Association between hypertension and impaired lung function among adults: A systematic review and meta-analysis

M.L. Dilakshi Lekamge[1*], Anuradhani Kasturiratne[1], Malay Kanti Mridha[2], John Chambers[3]

[1]Department of Public Health, Faculty of Medicine, University of Kelaniya, Sri Lanka

[2]James P Grant School of Public Health, BRAC University, Bangladesh

[3]Faculty of Medicine, School of Public Health, Imperial College London

* Corresponding author

Email: dilakshi.lekamge@gmail.com (MLD)

Abstract

Background: Impaired lung function and hypertension are both significant global public health concerns, and their potential association has recently drawn considerable interest. This systematic review and meta-analysis aim to investigate the association between impaired lung function and hypertension, and vice versa.

Methods: We searched CINAHL (EBSCOhost), MEDLINE (PubMed), Scopus and Web of Science up to 22nd July 2025 for observational studies involving adults (≥ 18 years) reporting hypertension and impaired lung function. Grey literature was also searched, and data extraction was verified independently. The review was registered with PROSPERO (CRD42023427631). Random effects models estimated pooled ORs with 95% CIs. Subgroup analysis and meta-regression were performed to identify potential sources of heterogeneity. Quality assessment was conducted using Newcastle-Ottawa Scale and JBI checklist and publication bias were appraised.

Results: This systematic review included 28 articles, of which 26 articles were selected for the meta-analysis. Of these, 17 studies (n=134823) examined impaired lung function as the exposure, while 9 studies (n=12522) investigated hypertension as the exposure. Our findings revealed that the pooled unadjusted effect of lung function impairment on hypertension was 1.70 (95% CI: [1.53–1.88]), while the pooled adjusted effect was lower at 1.40 (95% CI: [1.31–1.49]). In contrast, the pooled unadjusted effect of hypertension on lung impairment was 3.00 (95% CI: [1.86 – 4.82]), but the pooled adjusted effect decreased to 1.94 (95% CI: [1.51 – 2.50]). The findings indicate obstructive, restrictive and mixed lung function impairments are significantly associated with

hypertension. Restrictive lung impairment consistently shows a stronger association with hypertension compared to obstructive impairment when impaired lung function is the exposure.

Conclusion: This study concludes that there is a significant positive relationship between impaired lung function and hypertension, with temporal evidence supporting a causal pathway from impaired lung function to hypertension, though the reverse causal direction lacks such evidence.

Introduction

Hypertension is a widely recognized leading risk factor for cardiovascular disease [1] and a growing global public health concern, being a significant cause of morbidity and mortality [2]. Hypertension typically remains asymptomatic until complications arise, as long as the tissues continue to receive adequate blood supply. As a result, the condition often goes undetected until the occurrence of a precipitous event, unless blood pressure is regularly monitored.

It is reported that global burden of high blood pressure is over 1 billion individuals [1] accounting for an estimation of 17.9 million lives annually or 31% of global deaths [3].

Globally, the prevalence of hypertension has been steadily rising. In 2000, 26.4% of adults were affected, with predictions indicating a 60% increase by 2025, reaching 29.2%, or approximately 1.56 billion people [4]. By 2008, around 40% of adults aged 25 and above worldwide had high blood pressure, including those on antihypertensive medication, with the highest prevalence in the African Region (46%) and the lowest in the American region (35%) [5]. A later estimate found that the global prevalence of hypertension among adults to be 30–45% [6] [7], with age-standardized prevalence rates of 24% in men and 20% in women in 2015 [7] [8]. By 2025, hypertension is estimated to cause 7.5 million deaths, resulting 57 million disability-adjusted life years (DALYs) [4].

It is imperative to consider early detection of hypertension in broader perspective to address the significant health and economic burden of cardiovascular diseases as yet preventive assessments typically begin only after the age of 40 years [9]. It has been identified that hypertension is responsible for an estimated 54% of all strokes and 47% of all ischemic heart disease globally [10] and with adequate treatment the risk of major cardiovascular events including stroke, coronary artery disease, and congestive heart failure [11] can be reduced.

Pulmonary function tests are essential in clinical practice for identifying the functional status of the lungs including airway obstruction and other ventilatory defects [12], with spirometry being the most commonly performed standard test to assess lung function by measuring the rate and volume of expired air [13], providing the key outcomes such as forced expiratory volume in one second (FEV_1), forced vital capacity (FVC) and the FEV_1/FVC [12]. Lung function measured by these spiometric indices depends on height, weight, age and gender [14] acting as an important predictor of morbidity and mortality [15], declining slowly throughout the adult life, even in healthy individuals with an accelerated decline often observed after 70 years [14].

Obstructive airway diseases (OADs) include asthma and chronic obstructive pulmonary disease (COPD) [16], whereas alteration in the parenchyma, pleura, and chest wall [17] result in restrictive lung function impairment causing several underlying conditions and diseases, such as interstitial lung diseases, pleural effusions, neuromuscular diseases, thoracic deformities and obesity [18], which can be expressed as a reduction in FVC with normal FEV_1/FVC.

Being a major cause of global morbidity and mortality, Chronic obstructive pulmonary disease (COPD) is considered to be the third leading cause of death worldwide in 2030 [19]. Even though smoking is the major cause of COPD, occupational exposures, biomass exposure and exposure to air pollutants have substantial effects on the development of OADs resulting lung function impairment, especially those living in Asia and Africa [16], [20].

Several studies have demonstrated the interaction between the respiratory and cardiovascular systems in pathophysiological contexts since the early 1990s [21], [22], with Forced Vital Capacity (FVC) serving as a significant predictor of future cardiovascular disease and hypertension, irrespective of the underlying pathophysiological mechanisms [23] [24] [25] [26]. Chronic obstructive pulmonary disease (COPD) characterized by airflow obstruction often co-exists with cardiovascular disease (CVD) and hypertension [27]. Moreover, restrictive lung impairment

has also been linked to several cardiovascular disease (CVD) risk factors, such as obesity [28], diabetes mellitus [29], dyslipidemia [30], and hypertension [31].

Hypertension and impaired lung function are both significant public health concerns, and their potential association has recently drawn considerable interest. Several epidemiological studies have revealed the association between hypertension and its impact on lung function [16,24,32–39]. Moreover, evidence also suggests that individuals with lung function impairment may have a risk of developing hypertension [40]. However, some researchers found no evidence of an association between airflow obstruction and hypertension [41]. Some studies have revealed that impaired lung function could be attributed to the drugs used to treat hypertension, particularly beta blockers, rather than hypertension itself [37]. However, other researchers have suggested a contrasting point of view, emphasizing that hypertension risk could also be modulated by the prolong use of higher doses of inhaled steroids for treating chronic respiratory conditions [42]. Nonetheless, studies have identified that age and smoking habits accounted for the association between cardiovascular disease and hypertension with airflow obstruction in the general population [27].

To date there has not been either a systematic review or a meta-analysis to explore the association between hypertension and impaired lung function and vice versa. Therefore, we used the available data from cross-sectional, prospective longitudinal, and retrospective cohort studies to examine the literature and to perform a systematic review to ascertain the association between hypertension and impaired lung function and to quantify such association using meta-analysis techniques.

Materials and methods

Systematic review of the literature and meta-analysis were conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines [43]. The protocol for this systematic review and meta-analysis was pre-registered on the International

prospective register of systematic reviews (PROSPERO 2023 CRD42023427631) and is available at : https://www.crd.york.ac.uk/PROSPERO/view/CRD42023427631 (S1 File).

Search Strategy

We searched for relevant studies published from the database inception to 22nd July 2025 from four bibliographic databases namely CINAHL (EBSCOhost), MEDLINE (PubMed), Scopus and Web of Science. The searches were conducted without any language restrictions and limited to human research. Unpublished studies were also sought. Grey literature was searched through Google Scholar, ProQuest and snowballing method, where the references of relevant papers were hand-searched. The searches were rerun prior to the final analysis and any further studies were identified and retrieved for inclusion.

The following search strategy was developed in order to conduct the systematic literature search and capture relevant records from each of the four databases: (Hypertension OR "high blood pressure" OR "elevated blood pressure" OR "increased blood pressure" OR "raised blood pressure" OR "Hypertens*") AND ("forced expiratory volume" OR "forced vital capacity" OR "timed vital capacity" OR "vital capacity" OR "spirometry" OR "respiratory physiological phenomena*" OR "respiratory physiological phenomenon*" OR "lung pathophysiology" OR "total lung capacit*" OR "impaired lung function" OR "declined lung function" OR "reduced lung function" OR "limited lung function" OR "reduced spirometry" OR "impaired spirometry" OR "reduced FEV1" OR “reduced forced expiratory volume in 1 second” OR "reduced FVC" OR "reduced forced expiratory volume" OR "reduced VC" OR "reduced forced vital capacity" OR "FEV1/FVC ratio") AND ("adult*" OR "elder*"). A simplified search strategy was used to search the relevant other sources: (hypertension AND “impaired lung function”).

Selection Criteria

Studies that met the following criteria were included in this systematic review and meta-analysis: (1) observational studies (cohort, case-control and cross-sectional studies); (2) studies that included adult males or females ≥18 years who have been recruited in the study irrespective of their comorbidity; (3) studies that identified the incidence or prevalence of hypertension in adults with impaired lung function or impaired lung function in adults with hypertension; (4) studies that found an association between hypertension and impaired lung function or vice versa and (5) studies based on spirometric measurements to assess lung function.

We excluded (1) articles of reviews (literature reviews, systematic reviews, and meta-analyses), qualitative studies, trials registers, case reports, case series, book chapters, letters to editors, protocols, and conference proceedings; (2) studies comprising patients with acute respiratory diseases (Example: Bronchitis) and physical disability that may affect lung function (scoliosis and kyphosis); (3) studies of patients contraindicated for doing spirometry (recent myocardial infarction, heart failure), surgery to eyes (cataract surgery, glaucoma), chest or abdomen done less than 3 months prior to the study; (4) studies involving pregnant women; (5) articles in which the definition of hypertension and impaired lung function remain unclear and (6) studies that do not mention the method of measuring lung function.

The articles were selected based on the definition of hypertension as systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg, or the use of antihypertensive medication at the time of examination or self-reported history of hypertension or physician diagnosis of hypertension. This definition was considered irrespective of the type of device used (mercury sphygmomanometer or digital blood pressure monitor), the time of measuring the blood pressure (daytime, night-time, or over a continuous 24-hour period), the number of blood pressure readings taken (two or three blood pressure readings in succession) and the measurement location (clinic, home or office). We only accepted the articles where lung function impairment was

assessed based on FVC (forced vital capacity), FEV_1 (forced expiratory volume in 1 second) and FEV_1/FVC spirometric measurements and where the lung impairment was defined according to the lower limit of normal (LLN, <5th percentile) of the FEV_1/FVC ratio calculated from the reference equations or FEV_1/FVC < 0.70 or either any of lung impairment types: obstructive, restrictive or mixed were indicated. No interventions were considered.

Screening

All records identified during the database search were pooled and the duplicates were removed using the Zotero 7.0.11 reference management software. The PRISMA flow diagram was used to summarize the selection process (Fig 1). Titles and abstracts of studies retrieved using the search strategy were screened independently by one reviewer (D.L.) to identify studies that meet the afore-mentioned inclusion criteria. The full text of the studies was independently assessed for eligibility by two reviewers (D.L. and A.K.). Disagreements between individual judgments were resolved through the discussion between reviewers.

Fig 1. PRISMA Flow Diagram of systematic review and meta-analysis.

Data Extraction

Data were extracted by using a data extraction table which was designed with the use of Microsoft Excel by one author (D.L.) and the details of the extraction were subsequently verified by two different independent authors (A.K. and M.M). Any disagreements were identified and resolved through discussion. The data extracted included authors, title, year of publication, study setting (region and country), study design, population, study period, inclusion and exclusion criteria of the study, sample size, gender, number of male and female individuals, mean age, mean body mass

index and ethnicity of the participants, relevant variables, statistical method used, odds ratios (ORs) and 95% confidence intervals (CIs), exposure and the outcome, findings, and limitations. Prevalence of lung function impairment among hypertensive and non-hypertensives, and prevalence of hypertension among lung function impaired and normal lung function individuals were also extracted from the included studies. When a study reported more than one method of assessing the impaired lung function using the spirometric indices, effect sizes of different indices were extracted and analysed as separate studies. For studies where hypertension-lung function association was not the primary research question, we extracted relevant data from baseline characteristics tables.

Authors of relevant studies without the required data were contacted via e-mail to request sharing of unpublished data.

Quality Assessment

The full-text articles meeting eligibility were examined by two review authors (D.L. and A.K.) independently to assess the risk of bias. The Newcastle-Ottawa Scale (NOS) (S4 and S5 Files) or Joanna Briggs Institute (JBI) critical appraisal checklist (S6 File) were used as appropriate tools to assess the quality of included studies. The quality of the selected cohort and case-control studies was evaluated using the NOS, which is based on a star-rating systems and assigns scores ranging from 0 to 9 based on three domains: section, comparability and outcome/exposure with the maximum score of nine reflects the highest quality [44]. Articles with scores of 7 or above were rated as high quality, those with scores between 5 and 6 were considered average-quality, and those with scores of 4 or below were categorized as low quality [45].

For qualitative assessment of the cross-sectional studies, the JBI Critical Appraisal Checklist comprising 8 questions was used [46]. This checklist evaluates various aspects such as sample selection, subject description, exposure and subject condition measurement, identification and control of confounding factors, outcome assessment, and statistical analysis. Each item was rated as

yes, no, unclear, or not applicable. If the answer was yes, the question was assigned a score of 1, whereas a score of 0 was assigned when the answer indicated no, unclear, or not applicable. Studies scoring 7 or above are deemed to have a low risk of bias and high quality, scores between 4 and 6 indicate a moderate risk or moderate quality, and scores below 4 suggest a high risk of bias or low quality [45]. Any disagreements were identified and resolved through discussion.

Statistical Analysis

Odds ratios (OR) were extracted where available, or odds ratios were calculated from reported data or raw data received from authors to express the association between hypertension and impaired lung function and vice versa. The extracted raw data was used to compute the pooled odds ratio (OR) estimates with 95% confidence interval (CI) to assess the strength of the association between hypertension and impaired lung function as well as the association between impaired lung function and hypertension.

Studies were separately analyzed based on hypertension as the exposure and impaired lung function as the outcome, and vice versa. Initial meta-analyses were conducted using unadjusted ORs where available in the selected observational studies to identify whether there is a significant bidirectional association between hypertension and impaired lung function and followed up with the meta-analyses of the adjusted ORs obtained from the selected studies.

When a study has been conducted in several sites and if the site level information is available, those were included in the meta-analyses as different samples.

Considering the inter-study variations including differences in study design, potential differences in study populations and methodologies of retrieved studies meta-analyses were conducted to estimate the pooled effect size using the random-effect model. Forest plots were generated for each meta-analysis to illustrate the effect sizes and confidence intervals of each study and the pooled effect size.

The heterogeneity across the included studies was measured using Cochran's Q test and the statistical heterogeneity was quantified using I^2 statistic, in which an I^2 value of 25%, 50%, and 75% suggesting a low, moderate, and high degree of heterogeneity respectively [47,48]. Unless otherwise specified, outcomes were deemed statistically significant at $p < 0.05$.

To determine potential sources of heterogeneity subgroup analyses were performed by stratifying studies according to the study design, lung function impairment type, the country where the study was conducted, the geographical continent of study and adjustment relevant confounding factors (yes or no) to determine how the association between hypertension and impaired lung function and vice versa differ in terms of the above stratified variables.

To further detect the sources of heterogeneity, if a minimum of 10 studies were pooled a meta-regression was conducted considering the adjustments done for the following potential confounding variables: age, sex, smoking, Body Mass Index (BMI), education, race (black or white), physical inactivity, alcohol consumption levels, diabetes status, dyslipidemia, household income level, waist circumference, obesity, residence, C-reactive protein (CRP) and macronutrient intake protein carbohydrate total fat. Due to the limited number of studies within the analyses, the meta-regression was only conducted during the analysis of impaired lung function as the exposure and hypertension as the outcome.

Potential publication bias was graphically identified using funnel plots and assessed through the Egger's test to quantify any publication biases captured by the funnel plots. If significant publication bias was detected, a trim-and-fill method was performed to examine whether studies should be imputed to make the results more symmetrical to minimize the effects of publication bias [49,50].

"Leave-one-out" analysis was used to assess whether any one study has a dominant effect on the outcomes. Further, based on the quality assessment, sensitivity analysis was performed by excluding one study at a time and assessing whether the results are strongly influenced by a single

study in order to exclude poor-quality studies. Studies with NOS quality rating with 4 or below and JBI score below 4 were removed and the meta-analyses were repeated to see if the association stood still. All statistical analysis were conducted using R Studio software (R 4.5.1; R Foundation) using the meta package [51].

Results

Selection of studies

A total of 7434 studies were identified during the initial search, with 7379 found through databases and 55 identified through other methods (Fig 1). After removing 1410 duplicates, 6024 unique records remained. These were screened based on titles and abstracts, leading to the exclusion of 5946 studies that did not meet the inclusion criteria. A total of 78 full-text articles were assessed for eligibility, of which 53 were excluded for reasons such as no definition of hypertension (n = 16), differing hypertension definitions (n = 13), no cutoff for impaired lung function (n = 15), and failure to address impaired lung function (n = 9), ultimately including 28 articles in the review (Table 1). Based on the availability of the required odd ratios, only 26 articles were included in the meta-analysis.

Study Characteristics

The summary of the study characteristics of the included studies in the systematic review can be found in Table 1 and Table 2. There were 22 cross-sectional studies [18,24,27,33,35–39,41,42,52–62], 5 case-control studies [16,32,34,63,64] and 1 cohort study [40]. Of these, 17 studies examined impaired lung function as exposure and hypertension as the outcome, while 11 studies investigated hypertension as the exposure and impaired lung function as the outcome.

Exposure as impaired lung function and outcome as hypertension

The 17 studies included in this study consisted of 14 Cross sectional, 2 case-control and 1 cohort study spanning for a period of 30 years (1989 – 2019) comprised a total of 134823 participants, of whom 51.4% were female. Mean age across many included studies fell between 30 and 60 years (n = 10/17, 58.8%). Four studies were conducted in the United States; three in Korea; three studies combined countries globally; and the remaining studies were conducted in Australia, Austria, Brazil, Iran, Italy, Poland and Sweeden. Two studies comprised an exclusively male population and the rest included both males and females. The type of lung function impairment assessed varied among the included studies. Specifically, nine studies focused only on obstructive impairment, two studies only on restrictive impairment, five studies on both obstructive and restrictive lung impairments, and one study assessed obstructive, restrictive and mixed lung impairments (Table 1).

Table 1. Characteristics of the 17 included observational studies with hypertension as the outcome.

Study (Author, year)	Continent	Country	Study Design	Study Period	Sample Size	Male (%)	Age (Years) Mean ± SD	Adjusted Factors	Lung function impairment type	Major Findings
Bozek et al., 2016	Europe	Poland	CCS	2013 - 2014	3183	53.7	67.43 ± 5.7		Obstructive	Asthmatics had a significantly higher prevalence of HT.
Dharmage et al., 2023	Australia	Australia	CSS	2012–2016	2422	48.47			Restrictive Obstructive Mixed	Individuals with the restrictive only pattern had the significantly highest prevalence of HT.
Di Raimondo et al., 2020	Europe	Italy	CCS	2018 - 2019	80	37.5	52.1 ± 12.5	Age, sex, diabetes, fasting glucose, BMI	Obstructive	Once adjusted, asthma (OR = 3.66, 95% CI: 1.29–11.1, p = 0.008), and severe asthma (OR = 4.32, 95% CI:1.88–9.54, p < 0.001), were independently and significantly associated with an increased risk of HT.
Ferguson et al., 2014	North America	USA	CSS	May 2004 - April 2006 and July 2007 December 2009	812	33	46 ± 14	History of OSA, Age, sex, BMI, Smoking, asthma related variables	Obstructive	HT was significantly associated with lower FEV_1% (particularly 60-69%) and OSA, with stronger associations observed in combined OSA categories.
Jo et al., 2015	Asia	Korea	CSS	2010 - 2012	4057	100	56.89 ± 10.2	Age	Obstructive	HT was significantly more prevalent in the COPD group compared to the non-COPD group in age-adjusted analyses.
Kaufmann et al., 2024	Europe	Austria	CSS	2011	9466	46.5			Obstructive	Arterial HT was significantly more common in individuals with AL than in those with normal lung function.
Kiani & Ahmadi, 2021	Asia	Iran	CSS	2015 - 2019	6961	47.4	49.44 ± 9.29	Age, sex, education level, BMI, smoking status	Obstructive	A significant association was found between obstructive lung impairment and HT, with a 30.2% prevalence in COPD patients and an adjusted OR of 1.4 (95% CI: 1.02–1.99) compared to healthy individuals.

Table 1. continued

Study (Author, year)	Continent	Country	Study Design	Study Period	Sample Size	Male (%)	Age (Years) Mean ± SD	Adjusted Factors	Lung function impairment type	Major Findings
Kim et al., 2017	Asia	Korea	CSS	2010–2012	4043	100	57.05 ± 10.7	Age, BMI, smoking status, diabetes, metabolic syndrome, stroke	Obstructive	COPD was significantly and independently associated with HT (adjusted OR = 1.71, 95% CI: 1.37–2.13, $p < 0.001$). The association between COPD and HT remained significant even after adjusting for age and smoking.
Kulbacka-Ortiz et al., 2022	Asia, Africa, Europe, North America, Australia	Turkey, Algeria, Norway, Malawi, SA, Kyrgyztan , Sri Lanka, Benin, Morocco, China , Germany, Poland, USA, Portugal, England, NL, Philippines, India, Malaysia, Iceland, Saudi Arabia, Austria, Tunisia, Australia, Estonia, Albania, Sweden, Canada	CSS		22764	47.9	55.05 ± 10.4	Sex, age, BMI, smoking status, pack-years, education	Restrictive	After adjusting for age, sex, education, BMI, and smoking, HT was significantly associated with a higher likelihood of restricted spirometry (OR = 1.50, 95% CI: 1.39–1.63), with females showing a stronger association.

Table 1 continued

Study (Author, year)	Continent	Country	Study Design	Study Period	Sample Size	Male (%)	Age (Years) Mean ± SD	Adjusted Factors	Lung function impairment type	Major Findings
Lindberg et al., 2011	Europe	Sweden	CSS	2002 - 2004	1986	54.6	64.55	Gender, age, BMI, smoking habits	Restrictive Obstructive	COPD stage I was not significantly associated with HT (OR = 1.26, 95% CI: 0.99–1.61). COPD stage ≥II was **significantly** associated with increased risk of HT (**OR = 1.41**, 95% CI: 1.08–1.61). RLF was **not significantly** associated with HT (**OR = 1.36**, 95% CI: 0.98–1.89).
Mannino et al., 2008	North America	USA	Cohort Study	1989 - 1990 5 years of Follow up	20296	44.5		Age, sex, race, smoking status, education level, BMI.	Restrictive Obstructive	GOLD stage 2, 3, or 4 COPD, as well as RLF, were significantly associated with a higher prevalence of HT (OR =1.4, 95% CI:1.2–1.7 for GOLD 2; OR = 1.6, 95% CI: 1.3–1.9 for GOLD 3/4; and OR = 1.3, 95% CI: 1.1–1.6 for RLF), while GOLD stage 1 was not significant.
Mannino et al.2012	East Asia, West Asia, Central Europe, Northern Europe, North America, Southeast Asia, Australia	China, Turkey , Austria, SA, Iceland, Germany, Poland, Norway, Canada , USA, The Philippines, Australia, UK,	CSS	2008	9762	47.8		Age, smoking status, BMI, site (Adjusted when the exposure is restricted and obstructed separately)	Restrictive Obstructive	Both obstructive and RLF impairments were significantly associated with a higher prevalence of HT, with adjusted OR of 2.08 (95% CI: 1.80–2.41) for restricted spirometry and 1.44 (95% CI: 1.25–1.65) for obstructive spirometry, compared to normal lung function.

		Sweden								

Table 1 continued

Study (Author, year)	**Continent**	**Country**	**Study Design**	**Study Period**	**Sample Size**	**Male (%)**	**Age (Years) Mean ± SD**	**Adjusted Factors**	**Lung function impairment type**	**Major Findings**
Methvin et al., 2009	North America	USA	CSS		508	40.6		Age, sex, smoking status, education, and BMI	Restrictive Obstructive	HT was significantly associated with RLF, while a non-significant association was observed with OLF, possibly due to sample size limitations.
Park et al., 2015	Asia	Korea	CSS	2007 - 2012	16151	43.2	57.5 ± 11.1		Restrictive Obstructive	HT prevalence increases significantly with the severity of airway obstruction in both men and women.
Sperandio et al., 2016	South America	Brazil	CSS		374	42.14	41 ± 14	Age, gender, race, education, self-reported CVD risk factors (SAH, diabetes, dyslipidemia, smoking, obesity, and physical inactivity), body composition (fat body mass), peripheral muscle function (PTQ and PTB), postural balance (COP-EO), and cardiorespiratory fitness (peak VO2).	Restrictive	HT was significantly associated with a restrictive lung pattern, even after adjusting for confounders, with an OR of 17.5 (95% CI: 1.65–184.8).

Table 1 continued

Study (Author, year)	Continent	Country	Study Design	Study Period	Sample Size	Male (%)	Age (Years) Mean ± SD	Adjusted Factors	Lung function impairment type	Major Findings
Triest et al., 2019	Asia, Africa, Europe, North America, Australia	Turkey, Algeria, Norway, Malawi SA, Kyrgyztan Sri Lanka, Benin, Morocco, China , Germany, Poland, USA, Portugal, England, NL, Philippines, India, Malaysia, Iceland, Saudi Arabia, Austria, Tunisia, Australia, Estonia, Albania, Sweden, Canada	CSS	As of November 2016	22764	47.9	55.05 ± 10.4	Age, sex, smoking (including pack-years), BMI, education	Obstructive	Significant unadjusted association; not significant after adjustment. Age and smoking explain most of the association.
Yang et al., 2020	North America	USA	CSS	2007–2012	13237	50.5	46.89 ± 15.6	Age, gender, race, BMI, education level, income level, smoking status, alcohol use, macronutrient intake (protein, carbohydrate, total fat), EOS%, NEU%, HT, DM and dyslipidemia	Obstructive	In COPD patients, decreased FEV_1% and FVC% predicted were significantly associated with higher ORs of HT, even after adjusting for confounders.

Abbreviations: AL: Airflow limitation; CCS: Case-Control Study; CSS: Cross-sectional study; BMI: Body Mass Index; OR: Odd Ratio; CI: Confidence Interval; OSA: Obstructive Sleep Apnea; FEV_1%: Percent predicted Forced Expiratory Volume in one second; COPD: Chronic Obstructive Pulmonary Disease; SA: South Africa; USA: United States of America; NL: Netherlands; RLF: Restricted lung function; UK: United Kingdom; CVD: Cardiovascular diseases; SAH: Systemic Arterial Hypertension;VO2: Oxygen uptake; COP-EO: Center of pressure – eyes open COP area while standing with eyes open; PTQ: peak Torque of quadriceps; PTB: Peak Torque of biceps; EOS%: Eosinophils percent; NEU%: Neutrophils percent; DM: Diabetes Mellitus; HT: Hypertension; FVC%: Percent predicted Forced Vital Capacity; OLF: Obstructive Lung Function; GOLD: Global Initiative for Chronic Obstructive Lung Disease

328

Exposure as hypertension and outcome as impaired lung function

The 11 studies had a combined total of 13332 participants, with data collection occurring between 1989 and 2018. This included 8 cross-sectional studies and 3 case-control studies. The percentage of female participants in the included studies ranged from 43.0% to 53.8%. Data on female proportion were missing for some studies and were not included in this range. Mean age across many included studies fell between 30 and 60 years (n = 8/11, 72.7%). Among the selected studies, three studies were carried out in India, while two others were conducted in Korea. The remaining studies took place in several other countries worldwide (Ethiopia, Iceland, Italy, Japan, Nigeria, and United States). The assessment of lung function impairment varied across the selected studies, with 2 studies focusing on restrictive type, 5 on obstructive type, 3 on both obstructive and restrictive impairments, and 1 addressing obstructive, restrictive and mixed lung function impairments (Table 2).

Table 2. Characteristics of the 11 included observational studies with impaired lung function as the outcome.

Study (Author, year)	Continent	Country	Study Design	Study Period	Sample Size	Male (%)	Age (Years) Mean ± SD	Adjusted Factors	Lung function impairment type	Major Findings
Birhan & Abebe, 2018	Africa	Ethiopia	CSS	2016	122	47.5	51 ± 7.1		Restrictive	Hypertensive patients exhibited significantly lower pulmonary function values (FVC, FEV_1) compared to controls, with a higher FEV_1% indicating a dominant restrictive pulmonary defect, while no significant association was found between pulmonary function and the severity of HT.
Femi-Adeoye et al., 2024	Africa	Nigeria	CCS	1st of May and the 21st of July 2017	210	46.2	50.2 ± 6.0	Age, WC, BMI	Restrictive Obstructive	Poor lung function was significantly more prevalent among hypertensives (33.3%) than normotensives (21%) (p=0.044) and restriction pattern was the predominant lung function abnormality. After adjusting for these factors respondents with high blood pressure in the hypertensive group were about three times more likely to have poor lung function (OR = 2.995, 95% CI: 1.243 – 7.171)
Ferrari et al., 2019	Europe	Italy	CCS	2006 and 2010 2007 - 2015	2463	49.3	49.5 ± 12.8	Sex, age, education, smoking habits, alcohol consumption, physical activity, BMI, comorbidity indicators (diabetes, HT, dyslipidaemia	Obstructive	HT was significantly associated with asthma (RRR = 1.41, 95% CI: 1.06–1.89).

Table 2 continued

Study (Author, year)	Continent	Country	Study Design	Study Period	Sample Size	Male (%)	Age (Years) Mean ± SD	Adjusted Factors	Lung function impairment type	Major Findings
Kim et al., 2021	East Asia	Korea	CSS	2016–2018	3195	50.5	45.09 ± 4.3	Age, sex, BMI, alcohol consumption, smoking status, educational level, household income level, residence	Obstructive	Presence of HT was significantly positively associated with early COPD.
Lee et al., 2020	Asia	South Korea	CSS	2014 - 2015	4644	32.1	54.01 ± 10.21	Age, sex, BMI, WC, lifetime smoking, alcohol consumption, aerobic physical activity engagement, HGS	Restrictive	HT with normal FPG was associated with reduced lung function, though the adjusted OR of 1.45 (95% CI: 0.91–2.33) did not reach statistical significance.
Margretardottir et al., 2009	Europe	Iceland	CSS	2004 - 2005	750	53.07	56.40 ± 10.9	HT, BMI, CRP, age, sex, current smoking, pack years	Obstructive	HT was significantly associated with lower FEV_1% and FVC%, especially in men, and this association remained significant after adjusting for age, sex, smoking, and pack-years.
Patil et al., 2012	Asia	India	CCS	2007 - 2008	200	57	49.53 ± 9.8		Obstructive	The prevalence of OAD was significantly higher in hypertensive individuals (16.66%), with HT being independently associated with reduced lung function (FEV_1/FVC < 70%) and showing an OR of 8.044, highlighting a strong link between HT and IPF.

Table 2 continued

Study (Author, year)	Continent	Country	Study Design	Study Period	Sample Size	Male (%)	Age (Years) Mean ± SD	Adjusted Factors	Lung function impairment type	Major Findings
Shah et al., 2014	Asia	India	CSS		60		54.39 ± 8.4		Restrictive Obstructive	Patients with HT demonstrated significantly lower pulmonary function test parameters compared to controls ($p < 0.05$), with a predominantly obstructive pattern observed in 74% of cases.
Taneda et al., 2004	North America	United States	CSS	1989 to 1994	678	53.2		Pulse wave velocity, sex, age, BMI, cholesterol ratio, HT status, diabetes status, drinking status, smoking status	Restrictive Obstructive	HT is significantly positively associated with abnormal FVC% and FEV_1%.
Utsugi et al., 2016	Asia	Japan	CSS	2010 to 2012	950	49.5	64.9 ± 8.7	Age, lifelong cigarette consumption, and the presence of HT or dyslipidemia,	Obstructive	HT tended to be associated with more severe airflow limitation (GOLD II/III), but this was not significant ($p = 0.09$). Presence of HT was a risk factor for airflow limitation (14.6%)
Yadav et al., 2015	Asia	India	CCS		60				Restrictive Obstructive Mixed	An inverse relation is found between HT and pulmonary functions predominantly restrictive type of pattern. While non-significant effects are observed with severity of illness.

Abbreviations: CCS: Case-Control Study; CSS: Cross-sectional study; FVC: Forced Vital Capacity; FEV_1: Forced Expiratory Volume in one second; FEV_1%: Percent predicted Forced Expiratory Volume in one second; FVC%: Percent predicted Forced Vital Capacity; HT: Hypertension; RRR: Relative Risk Ratio; BMI: Body Mass Index; COPD: Chronic Obstructive Pulmonary Disease; WC: Waist Circumference; FPG: Fasting plasma glucose; OR: Odd Ratio; CI: Confidence Interval; OAD: Obstructive Airway Disease; IPF: impaired pulmonary function; GOLD: Global Initiative for Chronic Obstructive Lung Disease; HGS: Handgrip Strength; CRP: C-reactive protein

Quality Assessment

When the risk of bias of included studies was evaluated using the NOS scale, for the studies investigating the impaired lung function as the exposure, one study indicated as high quality [40], whereas two studies were of average quality [63,64]. When using the JBI Critical Appraisal Checklist, 2 studies demonstrated a low risk of bias while 10 studies were identified to have a moderate risk of bias. Two studies indicated a high risk of bias. The risk of bias in included observational studies can be found in Tables 3 and 4.

Table 3. Risk of bias summary for the cohort and case-control studies with impaired lung function as the exposure.

Study (Author, year)	Study Design	Selection	Comparability	Exposure/ Outcome	Number of Stars
Bozek et al., 2016 [63]	Case Control Study	★★★★		★★	6
Di Raimondo et al., 2020 [64]	Case Control Study	★★	★★	★★	6
Mannino et al., 2008 [40]	Cohort Study	★★	★★	★★★	7

Table 4. Risk of bias summary for the cross-sectional studies with impaired lung function as the exposure.

Study	Quality Score
Dharmage et al., 2023 [52]	4
Ferguson et al., 2014 [42]	6
Jo et al., 2015 [54]	6
Kaufmann et al., 2024 [55]	2
Kiani & Ahmadi., 2021 [56]	6
Kim et al., 2017 [65]	7
Kulbacka-Ortiz et al., 2022 [18]	6
Lindberg et al., 2011[41]	6
Mannino et al., 2012 [58]	5
Methvin et al., 2009 [59]	5
Park et al., 2015 [60]	3
Sperandio et al., 2016 [61]	6
Triest et al., 2019 [27]	7
Yang et al., 2020 [62]	6

392

For the studies investigating hypertension as the exposure, two studies were in high quality, and one study was in average quality when evaluated using the NOS. According to the JBI checklist there were 3 studies with low risk of bias, 3 studies were with moderate risk of bias and two were having high risk of bias. The risk of bias of included observation studies can be found in Tables 5 and 6.

Table 5. Risk of bias summary for the case-control studies with hypertension as the exposure

Study (Author, year)	Study Design	Selection	Comparability	Exposure	Number of Stars
Ferrari et al., 2019 [34]	Case Control Study	★★★★	★★	★	7
Patil et al., 2012 [16]	Case Control Study	★★★	★	★★	6
Yadav et al., 2015 [32]	Case Control Study	★★★	★★	★★	7

Table 6. Risk of bias summary for the cross-sectional studies with hypertension as the exposure

Study	Quality Score
Birhan & Abebe., 2018 [33]	2
Femi-Adeoye et al., 2024 [53]	8
Kim et al., 2021 [35]	7
Lee et al., 2020 [36]	8
Margretardottir et al., 2009 [24]	6
Shah et al., 2014 [37]	3
Taneda et al., 2004 [38]	5
Utsugi et al., 2016 [39]	5

Association between hypertension and impaired lung function

Impaired lung function as the exposure and hypertension as the outcome

31 studies (17 original papers) reported the relationship between impaired lung function and hypertension (n= 192055) when using unadjusted odd ratios. Among those 23 studies consistently revealed a significantly higher association between impaired lung function and hypertension and the remaining 8 studies reported no significant relationship between impaired lung function and

hypertension (Fig 2). Overall, the summary estimate demonstrated that patients with impaired lung function had an approximately a significant two-fold higher risk of having hypertension compared with normal lung functioned individuals (unadjusted OR = 1.6957; 95% CI: [1.5312– 1.8779], $p < 0.0001$). The heterogeneity across the studies was significant ($I^2 = 84.2\%$, $p < 0.0001$).

Fig 2. Forest plot showing the association between impaired lung function and hypertension among adults when using impaired lung function as the exposure and hypertension as the outcome (Using unadjusted odd ratios).

Publication bias

Although the visual inspection of the funnel plot shows a little asymmetry (Figs 3 and 4), the results of the Egger's test for publication bias indicated that there is no significant asymmetry ($t = -0.22$, $df = 24$, $p = 0.8272$), suggesting no evidence of small-study effects. The bias estimate was -0.2191(SE = 0.9928) with multiplicative residual heterogeneity variance (τ^2) 7.5138. The intercept was estimated as b = 0.5474 (95% CI: 0.3828 to 0.7121). The test for the publication bias has not been significant (since $p > 0.05$, $t = -0.2207$), but the funnel plot showed some signs of asymmetry which could indicate publication bias. Five studies were omitted from the test, as the SE variable was missing.

Fig 3. Funnel plot for the studies with crude /unadjusted OR for impaired lung function as the exposure and Hypertension as the outcome.

Fig 4. Funnel plot with the regression line for the studies with crude /unadjusted OR for impaired lung function as the exposure and Hypertension as the outcome (The points are not symmetrically distributed around the regression line).

Of the 31 studies initially considered, five studies were excluded from the Trim and Fill method due to missing standard errors. The remaining 26 studies were included, and no additional studies were imputed (Fig 5) suggesting that there is no evidence of publication bias. The pooled effect size was 0.5145 [95% CI: 0.4033; 0.6257], $p < 0.0001$. $I^2 = 86.2$ (Substantial variability).

Fig 5. Trim and Fill Funnel plot for the studies with crude /unadjusted OR for impaired lung function as the exposure and Hypertension as the outcome.

86 studies (13 original papers) reported the relationship between impaired lung function and hypertension (n= 181371) when using adjusted odd ratios. Among those 31 studies consistently revealed a significantly higher association between impaired lung function and hypertension and the remaining 55 studies reported no significant relationship between impaired lung function and hypertension (Fig 6). Overall, the summary estimate demonstrated that patients with lung function impairment had an approximately a significant one-fold higher risk of having hypertension compared with normal lung functioned individuals (adjusted OR = 1.3986; 95% CI: [1.3107 – 1.4925],

$p < 0.0001$). It was found out that there was a significant substantial heterogeneity across the studies ($I^2 = 59.8\%$, $p < 0.0001$).

Fig 6. Forest plot showing the association between impaired lung function and hypertension among adults when using impaired lung function as the exposure and hypertension as the outcome (Using adjusted odd ratios).

Both visual inspection of the funnel plot (Figs 7 and 8) and the results of the Egger's test for publication bias indicated that there is no significant asymmetry ($t = 0.8403$, df= 84, $p = 0.4031$), suggesting no evidence of small-study effects. The bias estimate was 0.1728 (SE = 0.2056) and

multiplicative residual heterogeneity variance (τ^2 = 1.6001). The intercept was estimated as b = 0.1764 (95% CI: 0.0927 to 0.2602). The test for the publication bias has not been significant (since $p > 0.05$, $t = 0.84$), and there is no evidence of publication biased based on the symmetry of the funnel plot.

Fig 7. Funnel plot for the studies with adjusted OR for impaired lung function as the exposure and Hypertension as the outcome.

Fig 8. Funnel plot with the regression line for the studies with adjusted OR for impaired lung function as the exposure and Hypertension as the outcome (The points are symmetrically distributed around the regression line).

Although the Egger's test and visual inspection of the funnel plot indicated no significant publication bias, seventeen studies were imputed during the Trim and Fill method to correct for slight asymmetry (Fig 9). While these results suggest that small-study effects cannot be completely ruled out, the adjusted pooled effect size was only slightly reduced to 0.1622 [95% CI: 0.0819; 0.2425],

$p < 0.0001$, with I^2 = 36.5% (moderate variability), and the direction and statistical significance of the association remained consistent with the original findings.

Fig 9. Trim and Fill Funnel plot for the studies with adjusted OR for impaired lung function as the exposure and Hypertension as the outcome.

Hypertension as the exposure and impaired lung function as the outcome

14 studies (9 original papers) reported the relationship between hypertension and impaired lung function (n= 13740) when using unadjusted odd ratios. Among those 10 studies consistently

revealed a significantly higher association between hypertension and impaired lung function and the remaining 4 studies reported no significant relationship between hypertension and impaired lung function (Fig 10). Overall, the summary estimate demonstrated that patients with hypertension had an approximately a significant three-fold higher risk of having lung function impairment compared with normotensives (unadjusted OR = 2.9960; 95% CI: [1.8637 – 4.8161], $p < 0.0001$). The heterogeneity across the studies was significant ($I^2 = 84.7\%$, $p < 0.0001$).

Fig 10. Forest plot showing the association between hypertension and impaired lung function among adults (Using unadjusted odd ratios).

Publication bias

Visual inspection of the funnel plot (Figs 11 and 12) and Egger's test for publication bias both indicated significant asymmetry ($t = 3.72$, $df = 12$, $p = 0.0029$), suggesting evidence of small-study effects. The bias estimate was 2.9787 (SE = 0.8016) and multiplicative residual heterogeneity variance ($\tau^2 = 3.2089$). The intercept was estimated as b = - 0.2282 (95% CI: - 0.7597 to 0.3033). The test for the publication bias has been significant (since $p < 0.05$, $t = 3.72$), and there is evidence of publication biased based on the asymmetry of the funnel plot. Evidence suggests publication bias or small-study effects in the meta-analysis.

Fig 11. Funnel plot for the studies with crude /unadjusted OR for Hypertension as the exposure and impaired lung function as the outcome.

Fig 12. Funnel plot with the regression line for the studies with crude /unadjusted OR for Hypertension as the exposure and impaired lung function as the outcome (The points are not symmetrically distributed around the regression line).

Seven studies were imputed using the Trim and Fill method to correct for asymmetry in the funnel plot (Fig 13). After imputation the adjusted effect size was 0.4201 [95% CI: -0.3421; 1.1822], p = 0.2800. I^2 = 85.4 % (Substantial variability). Publication bias or small-study effects likely exist, but adjustment does not change the overall conclusion.

Fig 13. Trim and Fill Funnel plot for the studies with crude /unadjusted OR for Hypertension as the exposure and impaired lung function as the outcome.

6 studies reported the relationship between hypertension and impaired lung function (n= 10355) when using adjusted odd ratios. Among those 4 studies consistently revealed a significantly higher association between hypertension and impaired lung function and the remaining 2 studies reported no significant relationship between hypertension and impaired lung function (Fig 14). Overall, the summary estimate demonstrated that patients with hypertension had an approximately a significant two-fold higher risk of having lung function impairment compared with normotensives (adjusted OR = 1.9417; 95% CI: [1.5110 – 2.4953], p < 0.0001). It was found out that there was no significant heterogeneity across the studies (I^2 = 0.0%, p = 0.5992).

Fig 14. Forest plot showing the association between hypertension and impaired lung function among adults (Using adjusted odd ratios).

The visual inspection of the funnel plot indicated some evidence of publication bias in this meta-analysis based on the asymmetry of the funnel plot and one study was omitted due to missing adjusted SE. (Fig 15). The number of studies (k=4) was too small to test for small study effects (k.min=10). Therefore, we refrained from performing Egger's test at this stage.

Fig 15. Funnel plot for the studies with adjusted OR for Hypertension as the exposure and impaired lung function as the outcome.

Three studies were imputed using the Trim and Fill method to correct the asymmetry in the funnel plot (Fig 16). After imputation the adjusted effect size was 0.4916 [95% CI: 0.0553; 0.9280], p = 0.0272. I^2 = 0.0% (no variability). The adjustment changed the overall conclusion indicating that there is no significant evidence of publication bias. Trim and fill analysis showed that three studies need to be imputed to make the results more symmetrical.

Fig 16. Trim and Fill Funnel plot for the studies with adjusted OR for Hypertension as the exposure and impaired lung function as the outcome.

Sensitivity Analysis

Sensitivity analyses using a leave-one-out approach conducted on the meta-analyses where the impaired lung function being exposure, revealed that the results remained statistically significant even when each study was removed individually, indicating robust findings for both unadjusted and adjusted ORs (Figs 17 and 18) (S1 and S2 Tables). Furthermore, the exclusion of studies with low quality or high risk of bias did not alter the results, further supporting the robustness of the findings.

For the unadjusted ORs, sensitivity analysis performed by excluding one study at a time from the meta-analysis conducted on the effect of hypertension on impaired lung function demonstrated consistent results, with no significant changes to the overall pooled effect size (Fig 19, S3 Table). Even the substantial heterogeneity among the studies remained unchanged. These findings indicate that the overall effect size is robust and not driven by any single study, confirming the reliability of the meta-analysis results. Further the exclusion of studies with high risk of bias or low quality did not alter the heterogeneity. However, no sensitivity analysis was conducted for the

adjusted OR, as the included studies showed no significant heterogeneity (I^2 = 0.0%), making additional analysis unnecessary.

Fig 17. The relationship between impaired lung function and hypertension. Leave one out sensitivity analysis of the unadjusted OR – ILF (Exposure) and HT (Outcome).

Fig 18. The relationship between impaired lung function and hypertension. Leave one out sensitivity analysis of the adjusted OR - ILF (Exposure) and HT (Outcome).

Fig 19. The relationship between hypertension and impaired lung function. Leave one out sensitivity analysis of the unadjusted OR.

Subgroup Analysis

Impaired lung function as the exposure and hypertension as the outcome

The subgroup analyses conducted using crude ORs showed stronger pooled effects for cross-sectional studies (OR = 1.7549, 95% CI: 1.5702–1.9614) compared to cohort and case-control studies, but no significant differences were found between study designs (Q = 0.77, p = 0.6820) (Fig 20). Significant subgroup differences were observed by country (Q = 30.73, p = 0.0003), with higher odds ratios in Italy and Brazil and smaller and non-significant effects were seen in Poland and Australia. Substantial heterogeneity was observed within the United States and Korea (Fig 21). The Mannino et al.[58] study was included by assigning it to selected countries, but the lack of country-specific sample sizes limited further disaggregation. Both obstructive (OR =1.6457; 95% CI: 1.4524–1.8648) and restrictive (OR = 1.9222 (95% CI: 1.7402–2.1231)) lung function impairments were significantly associated with the outcome, whereas the mixed lung function impairment type showed a weaker non-significant association. A significant subgroup difference was observed between the impairment types (Q = 7.32, p = 0.0257), suggesting that the strength of

association varied across different patterns of lung function impairment, with restrictive type showing the strongest association (Fig 22).

Fig 20. Forest plot for subgroup analyses by study design (Unadjusted ORs): Impaired lung function as the exposure and hypertension as the outcome.

Fig 21. Forest plot for subgroup analyses by country (Unadjusted ORs): Impaired lung function as the exposure and hypertension as the outcome.

Fig 22. Forest plot for subgroup analyses by Lung function impairment type (Unadjusted ORs): Impaired lung function as the exposure and hypertension as the outcome.

The subgroup analysis conducted using adjusted ORs provided insights into variations in odds ratios across different study designs, population characteristics, and adjustments for potential confounders. Case-control studies demonstrated higher odds ratios (OR = 3.66; 95% CI: 1.2477 – 10.7361), though differences by study design were not statistically significant (Q = 3.09, p = 0.2128) (Fig 23). Subgroup analysis by lung function impairment type showed that restrictive impairment (OR = 1.5632, 95% CI: 1.4422; 1.6944]) had a stronger association with the hypertension compared to obstructive impairment (OR = 1.2758; 95% CI: 1.1584; 1.4052), with the studies conducted to assess the restrictive impairment exhibiting lower variability (I^2 = 30.3%) (Fig 24). Subgroup analyses by country showed no significant differences in the pooled effects between groups (Fig 25).

Adjustments for confounders like sex, alcohol consumption levels, education, macro nutrient intake (protein, carbohydrate, total fat) and household income level significantly influenced the effect sizes (ORs), with unadjusted studies often showing higher odds ratios. Adjusting for physical inactivity and obesity results in a significantly higher odds ratio (OR = 17.51) compared to studies without such adjustments (OR = 1.40), indicating that these factors may strongly influence

the observed association. Although adjustments for BMI, diabetes status, smoking, race, and dyslipidemia were observed, but differences were not statistically significant (Table S4). The lack of statistical significance suggests that these factors do not substantially impact the overall effect in the context of this meta-analysis. A limitation of the subgroup analysis is the restricted availability of studies that included adjustments for specific variables. Of note, only one study accounted for physical inactivity, obesity, alcohol consumption, household income level, and macro nutrient intake, which limits the generalizability and robustness of the findings related to these moderators.

Subgroup analysis by continent was not conducted because the Mannino et al. [58] study included data from multiple continents, and the sample sizes for individual countries within these continents were unavailable. Thus, inability to accurately assign data to specific continents, the analysis would lack validity and could introduce bias. To ensure the robustness of the findings, the continent-based subgroup analysis was omitted. Since all studies involved both male and female participants, subgroup analyses by gender were not performed.

Fig 23. Forest plot for subgroup analyses by study design (Adjusted ORs): Impaired lung function as the exposure and hypertension as the outcome.

Fig 24. Forest plot for subgroup analyses by Lung function impairment type (Adjusted ORs): Impaired lung function as the exposure and hypertension as the outcome.

Fig 25. Forest plot for subgroup analyses by country (Adjusted ORs): Impaired lung function as the exposure and hypertension as the outcome.

Hypertension as the exposure and Impaired lung function as the outcome

The subgroup analyses conducted using crude ORs showed no statistically significant differences in odds ratios (ORs), between cross-sectional [OR = 2.4158, 95% CI: 1.8544 – 3.1472, I^2 = 55.7%, p = 0.00206] and case-control studies [OR = 8.1920, 1.4427 – 46.5157, I^2 =87.9%,

p < 0.0001] despite substantial variability in effect sizes, indicating study design did not significantly influence the association (Q =1.86, p = 0.1731) (Fig 26). In contrast, significant variability was observed by country (Q = 74.48, p < 0.0001) (Fig 27) and continent (Q = 56.41, p < 0.0001) (Fig 28), suggesting the association between hypertension and impaired lung function is influenced by geographic factors, with moderate heterogeneity within Asia (I^2 = 69.6%). Notable country-level variations in effect sizes were identified, with the highest ORs reported in studies from Ethiopia OR (31.50; 95% CI: 4.0730 – 243.619] and India (OR = 16.2955; 95% CI: 4.7113 – 56.3634) and the lowest in studies from Japan (OR = 1.6250; 95% CI: 1.0672–2.4744) and Italy (OR = 0.8120; 95% CI: 0.6310–1.0450), emphasizing the importance of regional factors. Analysis by lung function impairment type revealed the strongest association for mixed impairment (OR = 23.3330; 95% CI [1.9481 – 279.4615], followed by restrictive (OR = 6.3229; 95% CI [1.4644 – 27.3007]), obstructive impairments (OR = 2.2477; 95% CI [1.2944 – 3.9032]), and restrictive and obstructive impairment (OR = 1.8860; 95% CI [1.0137 – 3.5089]) though differences between subgroups were not statistically significant (Q = 5.54, p = 0.1362) (Fig 29). As all studies involved both male and female participants, subgroup analyses by gender were not performed.

Fig 26. Forest plot for subgroup analyses by study design (Unadjusted ORs): Hypertension as the exposure.

Fig 27. Forest plot for subgroup analyses by country (Unadjusted ORs): Hypertension as the exposure.

Fig 28. Forest plot for subgroup analyses by continent (Unadjusted ORs): Hypertension as the exposure.

Fig 29. Forest plot for subgroup analyses by lung function impairment type (Unadjusted ORs): Hypertension as the exposure.

The subgroup analysis conducted using adjusted ORs indicated that there were no statistically significant differences in ORs based on countries, continent, or adjustments for variables such as sex, education, physical inactivity, alcohol consumption, smoking, residence, household income level diabetes status, or waist circumference ($p > 0.05$) (Figs 30 and 31) (S5 Table). The analysis showed slight variations in odds ratios, with a stronger association for obstructive lung impairment (OR = 2.0331; 95% CI: 1.4145 – 2.9223) compared to restrictive impairments (OR = 1.7292; 95% CI: 1.1182 – 2.6740), but this difference was not statistically significant ($Q = 1.25$, $p = 0.5358$) (Fig 32).

Fig 30. Forest plot for subgroup analyses by country (Adjusted ORs): Hypertension as the exposure.

Fig 31. Forest plot for subgroup analyses by continent (Adjusted ORs): Hypertension as the exposure.

Fig 32. Forest plot for subgroup analyses by lung function impairment type (Adjusted ORs): Hypertension as the exposure.

The study from Japan [39] reports an odds ratio (OR) of 1.00, indicating no effect, and was excluded from the sub group analysis due to the lack of variation in its result. All included studies were cross-sectional; therefore, no subgroup analysis was performed by the study design due to a lack of variation in the study design. Subgroup analyses could not be performed for variables such as age, gender, BMI, and other comorbidities because either most studies failed to report primary data on these associations, or all the included studies were adjusted for the same factors— age, BMI, dyslipidemia, race (black or white), obesity, CRP and macronutrient intake protein carbohydrate total fat —leaving no variability to form distinct subgroups.

Meta-regression

In the univariate meta-regression of impaired lung function being the exposure, adjusting for certain moderators such as age, waist circumference, residence and CRP were flagged as reductant variables and dropped from the models due to collinearity or overlap with other predictors. This indicates that their effects could not be uniquely distinguished in the analysis. Adjusting for sex ($\hat{\beta} = -0.3780, p = 0.0025$) and education ($\hat{\beta} = -0.2768, p = 0.0047$) were negatively associated with the effect size, suggesting that including these adjusted factors in the model reduces the observed effect. Despite the inclusion on moderators, heterogeneity remained moderate (Table 8).

An initial meta-regression model including all potential moderators (both significant and non-significant from univariate analysis), resulted in high residual heterogeneity (I^2 = 99.12%), suggesting that the inclusion of non-significant variables did not improve the explanatory power of the model (R^2 = 3.44%). During the multivariable meta-regression which included only the significant variables from the univariate meta-regression (sex and education), the model explained 32.56% of the heterogeneity in effect sizes. However, neither of the adjusted moderators was statistically significant (Table 9), suggesting that these variables did not significantly contribute to the variation in impaired lung function among individuals with hypertension in this analysis.

Table 8. Results of the univariate meta-regression (Exposure: Impaired lung function).

Moderator	Estimate	SE	Z value	p value	95% CI	I^2 (%)	R^2 (%)	τ^2
BMI	-0.4153	0.2862	-1.4507	0.1469	-0.9763 to 0.1458	49.31	4.77	0.0438 (SE = 0.0176)
Sex	-0.3780	0.1249	-3.0270	0.0025	-0.6227 to 0.1332	40.39	32.04	0.0312 (SE = 0.0145)
Smoking	-0.4241	0.2844	-1.4910	0.1360	-0.9816 0.1334	49.30	4.83	0.0437 (SE = 0.0176)
Race	0.0791	0.1146	0.6901	0.4901	-0.1455 0.3036	49.51	0.00	0.0476 (SE = 0.0188)
Physical Inactivity	2.6597	46.7245	0.0569	0.9546	-88.9186 94.2381	50.92	0.00	0.0460 (SE = 0.0180)
Education	-0.2768	0.0978	-2.8287	0.0047	-0.4685 -0.0850	41.17	29.84	0.0323 (SE = 0.0147)
Alcohol Consumption Levels	-0.1025	0.2297	-0.4461	0.6555	-0.5527 0.3478	47.10	0.00	0.0487 (SE = 0.0192)
Diabetes Status	0.0709	0.1841	0.3849	0.7003	-0.2900 0.4317	47.63	0.00%	0.0490 (SE = 0.0192)
Dyslipidemia	-0.1024	0.2297	-0.4458	0.6557	-0.5526 0.3478	47.10	0.00%	0.0487 (SE = 0.0192)
Household Income Level	-0.1025	0.2297	-0.4461	0.6555	-0.5527 0.3478	47.10	0.00%	0.0487 (SE = 0.0192)
Obesity	2.6597	46.7245	0.0569	0.9546	-88.9186 94.2381	50.92	0.00%	0.0460 (SE = 0.0180)
Macronutrient Intake	-0.1025	0.2297	-0.4461	0.6555	-0.5527 0.3478	47.10	0.00%	0.0487 (SE = 0.0192)

Note: Variables flagged as redundant due to collinearity (age, waist circumference, residence, and CRP) were excluded from the univariate meta-regression analyses. I^2: residual heterogeneity/ unaccounted variability; R^2: amount of heterogeneity accounted for, τ^2: estimated amount of residual heterogeneity

Table 9. Results of the multivariable meta-regression: significant moderators from univariate (Exposure: Impaired lung function).

Moderator	Estimate	SE	Z value	p value	95% CI
Sex	-0.2520	0.1759	-1.4326	0.1520	-0.5967 to 0.0928
Education	-0.1386	0.1367	-1.0141	0.3105	-0.4066 to 0.1293

Discussion

To the best of our knowledge, this is the first systematic literature review and meta-analysis to date comprehensively evaluating the association between impaired lung function and hypertension and vice versa using data drawn from observational studies conducted globally. Our findings revealed that the pooled unadjusted effect of lung function impairment on hypertension was 1.70 (95% CI: [1.53–1.88]) with substantial heterogeneity (I^2 = 84.2%, $p < 0.0001$), while the pooled adjusted effect of lung impairment on hypertension was lower at 1.40 (95% CI: [1.31–1.49]), with moderate heterogeneity (I^2 = 59.8%, $p < 0.0001$). This suggests that adjustment for confounding factors reduced the strength of the association between hypertension and lung function impairment. In contrast, the pooled unadjusted effect of hypertension on lung impairment was 3.00 (95% CI: [1.86–4.82]) with considerable heterogeneity (I^2 = 84.7%, $p < 0.0001$), but the pooled adjusted effect decreased to 1.94 (95% CI: [1.51–2.50]), with no significant heterogeneity (I^2 = 0.0%, $p = 0.5992$). This indicates that adjustments for potential confounders significantly attenuated the association between hypertension and lung impairment, suggesting that the initial unadjusted effect might have been overestimated due to confounding factors. Thus, in the unadjusted analysis, hypertension had a stronger effect (OR = 3.00) when used as the exposure, compared to lung function impairment's effect on hypertension (OR = 1.70). However, after adjustments, both associations exhibit a decline, with

hypertension still showing a greater effect on lung impairment (OR = 1.94) compared to effect of lung function impairment on hypertension (OR = 1.40). Therefore, regardless of adjustments, hypertension appears to have a more substantial association with lung function impairment.

Although association of HTN with altered pulmonary function is not a new observation [26,66,67], the exact mechanisms underlying the bi-directional relationship between hypertension and impaired lung function remain obscure. Several studies have demonstrated that impaired lung function is associated with elevated levels of inflammatory markers [68–72], such as circulating C-reactive protein (CRP), and interleukin 6 causing increased risk of hypertension [69,70]. in The Pathophysiology of elevated cardiovascular risk in patients with chronic lung disease is multi factorial [73]. The overactivation of the sympathetic nervous system due to systemic inflammation [74–76], hypoxia [77] , reduced baroreceptor sensitivity [78] , inhibition of pulmonary stretch receptors [79], elevated muscle sympathetic nerve activity [80], inhibition of parasympathetic nervous system [73] together with vascular stiffness [78] result in hypertension with or without atherosclerosis (Fig 33). Further, higher forced vital capacity (FVC) is supposed to be a negative predictor of developing hypertension [25,26].

Fig 33. Pathophysiology of hypertension leading to CVD in patients with impaired lung function [73]**.**

Hypertension is linked to both increased systemic and pulmonary vascular resistance and increased vascular stiffness. Given the highly vascular nature of the lung and intimate anatomic coupling of vascular and parenchymal elements, several theories have been proposed to explain the relationship between hypertension and impaired lung function [81]. One proposed mechanism is that hypertension leads to left ventricular dysfunction, subsequently increasing left atrial pressure leading to elevated pulmonary artery pressure, which contributes to interstitial lung edema, and reduces lung compliance and functional residual capacity, ultimately lowering FEV_1 and FVC

values [82]. In addition to that, the increased peripheral vascular resistance associated with hypertension may impact the structure and function of the lungs and pulmonary circulation, causing small airway damage and impaired lung function [83].

The pooled odd ratio remained significant in subgroups for lung function impairment type and adjusted for race, macronutrient intake (protein, carbohydrate, total fat), obesity, and dyslipidemia only when impaired lung function was considered as the exposure. However, adjustments for BMI, diabetes status, race, dyslipidemia, and smoking did not show significant associations. Additionally, subgroups such as study design, country, and adjustments for alcohol consumption levels, macronutrient intake (protein, carbohydrate, total fat), household income level, obesity, and physical inactivity included only one study each, limiting the ability to draw firm conclusions from these subgroups.

The findings indicate obstructive, restrictive and mixed lung function impairments are significantly associated with hypertension, with restrictive lung impairment consistently showing a stronger association with hypertension compared to obstructive impairment when ILF is the exposure. Although subgroup differences were not statistically significant hypertension as the exposure shows a stronger association with mixed lung impairment. Adjustments reduce the strength of associations, highlighting the potential influence of confounding factors. These findings suggest that restrictive impairment may have a more consistent and robust association with hypertension, while mixed and obstructive impairments show stronger associations in certain contexts. This highlights the importance of accounting for lung impairment types and study design variability when examining the bidirectional relationship between hypertension and lung function.

In cross-sectional studies, a significant association was observed in both unadjusted and adjusted analyses when impaired lung function (ILF) was the exposure, as well as when hypertension was the exposure. Subgroup analysis indicated that study design did not significantly

influence the associations, as no significant differences were found between study designs in both unadjusted and adjusted analyses for either exposure-outcome relationship (Q values: 0.77–3.09, $p > 0.05$). Since cross-sectional studies do not provide the temporal relationship, the meta-analyses of both crude and adjusted ORs indicated that a significant association was even found in the included cohort studies when impaired lung function was taken as the exposure. Therefore, this evidence suggests a potential causal pathway from impaired lung function to hypertension, supported by cohort study data that establishes temporal sequence.

The quality assessment of the included studies provided crucial insight into the strength and reliability of the evidence. When impaired lung function was considered as the exposure, 17.65 % of studies were classified as high quality, suggesting a limited but robust subset of evidence in this direction. The majority of studies (70.6%) were of average quality, indicating a reasonable level of methodological soundness but with potential limitations, such as incomplete adjustments for confounders or moderate heterogeneity. Only 11.76% of studies were categorized as low quality, suggesting minimal risk of severely biased evidence in this analysis. Conversely, when impaired lung function was considered the outcome, the distribution shifted slightly, with 81.8% of studies classified as high or average quality, indicating a balanced level of reliability in this direction. However, 18.2% of studies were of low quality, raising concerns about potential biases in these findings. Such variability emphasizes the importance of interpreting the findings with caution, particularly where lower-quality studies contribute to the pooled estimates. The results highlight a need for future studies with rigorous designs and comprehensive adjustments to better clarify the bidirectional relationship between hypertension and impaired lung function.

Furthermore, publication bias was evident in some analyses, as indicated by asymmetry in the funnel plots although the Egger' s test results did not indicate any significance. Adjustments using Trim and Fill method shifted the effect sizes (adjusted ORs) strengthening the robustness of the results when hypertension was considered as the exposure, suggesting that publication bias or

small-study effects may have influenced the initial estimates. The exclusion of studies with low quality or high risk of bias did not alter the results, further supporting the robustness of the findings.

Strengths and limitations

This systematic review and meta-analysis have several strengths. No previous systematic review and meta-analysis have explored the bidirectional association between impaired lung function and hypertension therefore, this study provides new insights that may influence the care for patients with these two conditions. The large sample size increases the power and accuracy of pooled effect estimates, while the inclusion of studies with the same standard measurements of ILF and hypertension minimizes variability effects. A comprehensive search was done using explicit search strategies covering multiple databases without applying any language restrictions, which strengthened the completeness of the review and minimized the risk of selection or cultural bias, thereby not affecting the generalizability of the results. Another strength of this review is the effort taken to contact authors to request unpublished literature as to reduce publication bias. Sampling bias was reduced through independent and blind screening of titles and abstracts by two researchers. In addition, this meta-analysis included additional sensitivity and subgroup analyses to evaluate the findings of association between hypertension and impaired lung function and vice versa. The quality of the included studies was thoroughly assessed through NOS and JBI quality assessment tools.

Hand-searching of references were even conducted to reduce the likelihood of missing relevant data. The inclusion of cohort studies allowed exploration of temporal relationships and potential causality when impaired lung function was the exposure.

However, the potential limitations of this meta-analysis should be considered. Despite efforts to minimize heterogeneity through sensitivity, subgroup analyses, and meta-regression significant heterogeneity persisted across some studies. Despite efforts being made to include

unpublished studies by contacting authors via email, obtaining relevant raw data was unsuccessful. Our study focused on odds ratios (ORs), excluding studies with other indices such as relative risk or hazard ratios, and the limited adjustment for confounders across studies hindered comprehensive exploration of heterogeneity. While the quality of included studies varied and publication bias was detected, these factors did not significantly affect the validity of the findings, though caution is warranted in interpreting the results.

Conclusions

In conclusion, this systematic review and meta-analysis provide the first comprehensive evidence of a significant positive association between impaired lung function and hypertension. The available prospective evidence suggests impaired lung function contributes to subsequent hypertension risk, while support for the opposite causal direction is insufficient. However, the significant heterogeneity observed between studies warrants cautious interpretation of these findings. These findings pave the way for future research and highlight important considerations for clinical and public health interventions.

Moreover, the association between impaired lung function and increased risk of hypertension and the effect of hypertension on impaired lung function in this meta-analysis might be confounded by various factors. Therefore, future research should focus on identifying potential confounders specific to each condition, as well as those common to both, to ensure a more accurate interpretation of these findings. Large-scale, population based epidemiological studies are recommended to assess the impact of lung function impairment on hypertension and vice versa.

Acknowledgements

We extend our gratitude to all the authors who generously shared their data.

References

1. World Health Organization. Hypertension [Internet]. 2024 [cited 2024 Nov 9]. Available from: https://www.paho.org/en/topics/hypertension

2. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004 Jan;22(1):11–9.

3. World Health Organization. Cardiovascular diseases (CVDs) [Internet]. 2021 [cited 2024 Nov 10]. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

4. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet Lond Engl. 2005 Jan 15;365(9455):217–23.

5. World Health Organization. A global brief on hypertension□: silent killer, global public health crisis: World Health Day 2013 [Internet]. 2013 [cited 2024 Nov 14]. Available from: https://www.who.int/publications/i/item/a-global-brief-on-hypertension-silent-killer-global-public-health-crisis-world-health-day-2013

6. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013 Sept 4;310(9):959–68.

7. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018 Sept 1;39(33):3021–104.

8. Zhou B, Bentham J, Di Cesare M, Bixby H, Danaei G, Cowan MJ, et al. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. The Lancet. 2017 Jan;389(10064):37–55.

9. Jacobs D, Yatsuya H, Hearst M, Thyagarajan B, Kalhan R, Rosenberg S, et al. Rate of Decline of Forced Vital Capacity Predicts Future Arterial Hypertension The Coronary Artery Risk Development in Young Adults Study. HYPERTENSION. 2012 Feb;59(2):219-+.

10. Lawes CM, Hoorn SV, Rodgers A. Global burden of blood-pressure-related disease, 2001. The Lancet. 2008 May 3;371(9623):1513–8.

11. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507–20.

12. Ostrowski S, Barud W. Factors influencing lung function: are the predicted values for spirometry reliable enough? J Physiol Pharmacol Off J Pol Physiol Soc. 2006 Sept;57 Suppl 4:263–71.

13. American Lung Association. Pulmonary Function Tests [Internet]. 2024 [cited 2024 Nov 10]. Available from: https://www.lung.org/lung-health-diseases/lung-procedures-and-tests/lung-function-tests

14. Lazarus R, Gore CJ, Booth M, Owen N. Effects of body composition and fat distribution on ventilatory function in adults. Am J Clin Nutr. 1998 July;68(1):35–41.

15. Griffith K, Sherrill D, Siegel E, Manolio T, Bonekat H, Enright P. Predictors of loss of lung function in the elderly the cardiovascular health study. Am J Respir Crit CARE Med. 2001 Jan;163(1):61–8.

16. Patil V, Pujari B, Patil H, Munjal A, Agrawal V. Prevalence of obstructive airway disease by spirometric indices in non-smoker subjects with IHD and HTN. Lung India. 2012;29(3):241–7.

17. Mannino DM, Holguin F, Pavlin BI, Ferdinands JM. Risk factors for prevalence of and mortality related to restriction on spirometry: findings from the First National Health and Nutrition Examination Survey and follow-up. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2005 June;9(6):613–21.

18. Kulbacka-Ortiz K, Triest F, Franssen F, Wouters E, Studnicka M, Vollmer W, et al. Restricted spirometry and cardiometabolic comorbidities: results from the international population based BOLD study. Respir Res. 2022 Feb 17;23(1).

19. World Health Organization. World health statistics 2008. 2008;110.

20. Soriano, J. B., Kendrick, P. J., Paulson, K. R., Gupta, V., Abrams, E. M., Adedoyin, R. A., et al. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020 June;8(6):585–96.

21. Peabody FW. CLINICAL STUDIES OF THE RESPIRATION: IV. THE VITAL CAPACITY OF THE LUNGS AND ITS RELATION TO DYSPNEA. Arch Intern Med. 1917 Sept 1;XX(3):443.

22. Peters JP, Barr DP. Studies of the respiratory mechanism in cardiac dyspnea. Am J Physiol-Leg Content. 1920 Dec;54(2):335–44.

23. Engström G, Hedblad B, Valind S, Janzon L. Increased incidence of myocardial infarction and stroke in hypertensive men with reduced lung function. J Hypertens. 2001 Feb;19(2):295.

24. Margretardottir OB, Thorleifsson SJ, Gudmundsson G, Olafsson I, Benediktsdottir B, Janson C, et al. Hypertension, Systemic Inflammation and Body Weight in Relation to Lung Function Impairment—An Epidemiological Study. COPD J Chronic Obstr Pulm Dis. 2009 Jan 1;6(4):250–5.

25. Selby JV, Friedman GD, Quesenberry CPJ. Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol. 1990 June;131(6):1017–27.

26. Sparrow D, Weiss ST, Vokonas PS, Cupples LA, Ekerdt DJ, Colton T. Forced vital capacity and the risk of hypertension. The Normative Aging Study. Am J Epidemiol. 1988 Apr;127(4):734–41.

27. Triest FJJ, Studnicka M, Franssen FME, Vollmer WM, Lamprecht B, Wouters EFM, et al. Airflow Obstruction and Cardio-metabolic Comorbidities. COPD J Chronic Obstr Pulm Dis. 2019;16(2):109–17.

28. Yeh F, Dixon AE, Marion S, Schaefer C, Zhang Y, Best LG, et al. Obesity in Adults Is Associated With Reduced Lung Function in Metabolic Syndrome and Diabetes: The Strong Heart Study. Diabetes Care. 2011 Sept 15;34(10):2306.

29. Walter RE, Beiser A, Givelber RJ, O'Connor GT, Gottlieb DJ. Association between glycemic state and lung function: the Framingham Heart Study. Am J Respir Crit Care Med. 2003 Mar 15;167(6):911–6.

30. Leone N, Courbon D, Thomas F, Bean K, Jégo B, Leynaert B, et al. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. Am J Respir Crit Care Med. 2009 Mar 15;179(6):509–16.

31. Koo HK, Kim DK, Chung HS, Lee CH. Association between metabolic syndrome and rate of lung function decline: a longitudinal analysis. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2013 Nov;17(11):1507–14.

32. Yadav A, Sankhla M, Yadav K, Rahul. Association of Hypertension and Pulmonary Functions. International Multispecialty Journal of Health (IMJH). 2015;Vol-1(May).

33. Birhan MM, Abebe Y. Pulmonary Function Tests in Hypertensive Patients Attending Zewditu Memorial Hospital, Addis Ababa, Ethiopia. Int J Hypertens [Internet]. 2018;2018. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85057379168&doi=10.1155%2f2018%2f5492680&partnerID=40&md5=5bb839f079eb5fce31899c636c857897

34. Ferrari M, Piccinno E, Marcon A, Marchetti P, Cazzoletti L, Pirina P, et al. Chronic bronchitis without airflow obstruction, asthma and rhinitis are differently associated with cardiovascular risk factors and diseases. PLoS ONE [Internet]. 2019;14(11). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85074722939&doi=10.1371%2fjournal.pone.0224999&partnerID=40&md5=6bc9aa740f8fab74d569d058825c66f4

35. Kim T, Kim J, Kim JH. Characteristics and prevalence of early chronic obstructive pulmonary disease in a middle-aged population: Results from a nationwide-representative sample. Int J COPD. 2021;16:3083–91.

36. Lee J, Kwon D, Lee Y, Jung I, Hyun D, Lee H, et al. Hypertension Is Associated with Increased Risk of Diabetic Lung. Int J Environ Res Public Health. 2020 Jan;17(20):7513.

37. Shah S, Shaikh M, Gupta Y, Nahar P, Zingade U, Kowale A. Pulmonary Function Tests in Hypertension. International Journal of Pharma Sciences and Research (IJPSR). 2014;5(7):338–43.

38. Taneda K, Namekata T, Hughes D, Suzuki K, Knopp R, Ozasa K. Association of Lung Function with Atherosclerotic Risk Factors Among Japanese Americans: Seattle Nikkei Health Study. Clin Exp Pharmacol Physiol. 2004;31(s2):S31–4.

39. Utsugi H, Nakamura H, Suzuki T, Maeno T, Nagata M, Kanazawa M. Associations of lifelong cigarette consumption and hypertension with airflow limitation in primary care clinic outpatients in Japan. Respir Investig. 2016 Jan;54(1):35–43.

40. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008 Oct 1;32(4):962–9.

41. Lindberg A, Larsson LG, Rönmark E, Lundbäck B. Co-morbidity in mild-to-moderate COPD: Comparison to normal and restrictive lung function. COPD J Chronic Obstr Pulm Dis. 2011;8(6):421–8.

42. Ferguson S, Teodorescu MC, Gangnon RE, Peterson AG, Consens FB, Chervin RD, et al. Factors associated with systemic hypertension in asthma. Lung. 2014 Oct;192(5):675–83.

43. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009 July 21;6(7):e1000097.

44. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010 Sept;25(9):603–5.

45. Sun Y ting, Wu W, Yao Y tai. The association of vasoactive-inotropic score and surgical patients' outcomes: a systematic review and meta-analysis. Syst Rev. 2024 Jan 6;13(1):20.

46. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. JBI Evid Implement. 2015 Sept;13(3):147.

47. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003 Sept 6;327(7414):557–60.

48. Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006 June;11(2):193–206.

49. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000 June;56(2):455–63.

50. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997 Sept 13;315(7109):629–34.

51. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019 Nov;22(4):153–60.

52. Dharmage SC, Bui DS, Walters EH, Lowe AJ, Thompson B, Bowatte G, et al. Lifetime spirometry patterns of obstruction and restriction, and their risk factors and outcomes: a prospective cohort study. Lancet Respir Med. 2023 Mar;11(3):273–82.

53. Femi-Adeoye OM, Adebusoye LA, Muyibi SA, Sogaolu OM, Femi-Adeoye OO. Association between Hypertension and lung function among adult patients attending the general outpatient clinic of a tertiary hospital in Southwest Nigeria. Niger J Fam Pract. 2024;15(2):66–70.

54. Jo YS, Choi SM, Lee J, Park YS, Lee SM, Yim JJ, et al. The relationship between chronic obstructive pulmonary disease and comorbidities: A cross-sectional study using data from KNHANES 2010–2012. Respir Med. 2015 Jan;109(1):96–104.

55. Kaufmann CC, Breyer MK, Hartl S, Gross C, Schiffers C, Wouters EFM, et al. Association of Preserved Ratio Impaired Spirometry with Arterial Stiffness. Ann Am Thorac Soc. 2024 Sept;21(9):1289–98.

56. Kiani FZ, Ahmadi A. Prevalence of different comorbidities in chronic obstructive pulmonary disease among Shahrekord PERSIAN cohort study in southwest Iran. Sci Rep. 2021 Jan 15;11(1):1548.

57. Kim SH, Park JH, Lee JK, Heo EY, Kim DK, Chung HS. Chronic obstructive pulmonary disease is independently associated with hypertension in men: A survey design analysis using nationwide survey data. Medicine (Baltimore). 2017 May;96(19):e6826.

58. Mannino DM, McBurnie MA, Tan W, Kocabas A, Anto J, Vollmer WM, et al. Restricted spirometry in the burden of lung disease study. Int J Tuberc Lung Dis. 2012;16(10):1405–11.

59. Methvin J, Mannino D, Casey B. COPD Prevalence in Southeastern Kentucky The Burden of Lung Disease Study. CHEST. 2009 Jan;135(1):102–7.

60. Park HJ, Leem AY, Lee SH, Song JH, Park MS, Kim YS, et al. Comorbidities in obstructive lung disease in Korea: data from the fourth and fifth Korean National Health and Nutrition Examination Survey. Int J Chron Obstruct Pulmon Dis. 2015;10:1571–82.

61. Sperandio EF, Arantes RL, Matheus AC, Silva RP da, Lauria VT, Romiti M, et al. Restrictive pattern on spirometry: association with cardiovascular risk and level of physical activity in asymptomatic adults. J Bras Pneumol Publicacao Of Soc Bras Pneumol E Tisilogia. 2016 Feb;42(1):22–8.

62. Yang K, Wu Y, Chen D, Liu S, Chen R. The Impact of Lung Function on Extra-Pulmonary Diseases and All-Cause Mortality in US Adult Population with and without COPD. Clin Epidemiol. 2020;12:997–1005.

63. Bozek A, Rogala B, Bednarski P. Asthma, COPD and comorbidities in elderly people. J Asthma Off J Assoc Care Asthma. 2016 Nov;53(9):943–7.

64. Di Raimondo D, Musiari G, Benfante A, Battaglia S, Rizzo G, Tuttolomondo A, et al. Prevalence of arterial hypertension and characteristics of nocturnal blood pressure profile of asthma patients according to therapy and severity of the disease: The bada study. Int J Environ Res Public Health. 2020;17(18):1–13.

65. Kim SK, Bae JC, Baek JH, Jee JH, Hur KY, Lee MK, et al. Decline in lung function rather than baseline lung function is associated with the development of metabolic syndrome: A six-year longitudinal study. PLOS ONE. 2017 Mar 27;12(3):e0174228.

66. Lebowitz MD, Phibbs B, Robertson G, Holberg C, Knudson R, Burrows B. Vectorcardiographic and blood pressure correlates of obstructive pulmonary diseases in a community population. Chest [Internet]. 1986 Jan [cited 2024 Dec 29];89(1). Available from: https://pubmed.ncbi.nlm.nih.gov/2934231/

67. Lindgärde F, Furu M, Ljung BO. A longitudinal study on the significance of environmental and individual factors associated with the development of essential hypertension. J Epidemiol Community Health. 1987 Sept;41(3):220–6.

68. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009 May;33(5):1165–85.

69. Ishida S, Kondo S, Funakoshi S, Satoh A, Maeda T, Kawazoe M, et al. White blood cell count and incidence of hypertension in the general Japanese population: ISSA-CKD study. PloS One. 2021;16(2):e0246304.

70. Jayedi A, Rahimi K, Bautista LE, Nazarzadeh M, Zargar MS, Shab-Bidar S. Inflammation markers and risk of developing hypertension: a meta-analysis of cohort studies. Heart Br Card Soc. 2019 May;105(9):686–92.

71. Jiang R, Burke GL, Enright PL, Newman AB, Margolis HG, Cushman M, et al. Inflammatory Markers and Longitudinal Lung Function Decline in the Elderly. Am J Epidemiol. 2008 Sept 15;168(6):602–10.

72. Xu Q, Wu K, Yang Y, Chang R, Qiu H, Wang Y, et al. Association between sleep quality and pain intensity in mild patients with COPD: A community study. J Pain Res. 2021;14:2641–9.

73. Imaizumi Y, Eguchi K, Kario K. Lung Disease and Hypertension. Pulse Basel Switz. 2014 May;2(1–4):103–12.

74. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000 May 25;405(6785):458–62.

75. Sajadieh A, Nielsen OW, Rasmussen V, Hein HO, Abedini S, Hansen JF. Increased heart rate and reduced heart-rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease. Eur Heart J. 2004 Mar;25(5):363–70.

76. Jensen-Urstad M, Jensen-Urstad K, Ericson M, Johansson J. Heart rate variability is related to leucocyte count in men and to blood lipoproteins in women in a healthy population of 35-year-old subjects. J Intern Med. 1998 Jan;243(1):33–40.

77. Kario K. Obstructive sleep apnea syndrome and hypertension: ambulatory blood pressure. Hypertens Res Off J Jpn Soc Hypertens. 2009 June;32(6):428–32.

78. Mattace-Raso FUS, van den Meiracker AH, Bos WJ, van der Cammen TJM, Westerhof BE, Elias-Smale S, et al. Arterial stiffness, cardiovagal baroreflex sensitivity and postural blood pressure changes in older adults: the Rotterdam Study. J Hypertens. 2007 July;25(7):1421–6.

79. Heindl S, Lehnert M, Criée CP, Hasenfuss G, Andreas S. Marked sympathetic activation in patients with chronic respiratory failure. Am J Respir Crit Care Med. 2001 Aug 15;164(4):597–601.

80. Macefield VG. Firing Patterns of Muscle Vasoconstrictor Neurons in Respiratory Disease. Front Physiol. 2012 May 23;3:153.

81. Enright PL, Kronmal RA, Smith VE, Gardin JM, Schenker MB, Manolio TA. Reduced vital capacity in elderly persons with hypertension, coronary heart disease, or left ventricular hypertrophy. The Cardiovascular Health Study. Chest. 1995 Jan;107(1):28–35.

82. Schnabel E, Nowak D, Brasche S, Wichmann HE, Heinrich J. Association between lung function, hypertension and blood pressure medication. Respir Med. 2011 May;105(5):727–33.

83. Tamagawa E, Van Eeden SF. Impaired Lung Function and Risk for Stroke. Chest. 2006 Dec;130(6):1631–3.

Supporting Information

S1 File. PROSPERO Protocol.

S2 File. Completed PRISMA 2020 Checklist.

S3 File. Completed PRISMA 2020 Abstract Checklist.

S4 File. Newcastle - Ottawa Quality Assessment Scale for Cohort Studies.

S5 File. Newcastle - Ottawa Quality Assessment Scale for Case-Control Studies.

S6 File. JBI Critical Appraisal Checklist for Analytical Cross-Sectional Studies.

S7 File. The csv file containing all screened records.

S1 Table. Results of the sensitivity analysis - ILF (Exposure) and HT (Outcome) – Unadjusted analysis.

S2 Table. Results of the sensitivity analysis - ILF (Exposure) and HT (Outcome) – Adjusted analysis.

S3 Table. Results of the sensitivity analysis - HT (Exposure) and ILF (Outcome) – Unadjusted analysis.

S4 Table. Summary of subgroup analyses for the adjusted ORs (Exposure: Impaired lung function; Outcome: Hypertension) to explore the source of heterogeneity.

S5 Table. Summary of subgroup analyses for the adjusted ORs (Exposure: Hypertension; Outcome: Impaired lung function) to explore the source of heterogeneity.


Identification
Screening
Included
Identification of studies via databases (n = 7379)
Identification of studies via other methods (n = 55)
Records identified from:
CINAHL (EBSCOhost) (n = 178)
MEDLINE (PubMed) (n = 1117)
Scopus (n = 5672)
Web of Science (n = 412)
Records removed before screening:
Duplicate records removed (n = 1363)
Records identified from:
Google Scholar (n = 55)
ProQuest (n = 0)
Records (n = 6016)
Records (n = 55)
Records (n = 6071)
Records removed before screening: Duplicate records removed (n =15 + 32 = 47)
Records Screened (n = 6024)
Title Screening (n = 5540)
Abstract Screening (n = 399)
Abstract only (n = 7)
Full-text articles assessed for eligibility (n = 78)
Full-text articles excluded (n = 53)
• No hypertension definition (n = 16)
• Hypertension definition differs (n = 13)
• No cutoff for impaired lung function (n = 15)
• Impaired lung function not addressed (n = 9)
Articles included from snowballing (n = 3)
Studies included in the review (n = 28)
Studies included in the meta-analysis (n = 26)
• Exposure: Impaired Lung Function (n = 17)
• Exposure: Hypertension (n = 9)

Study	logOR	SE(logOR)	OR	95%-CI	Weight
Bozek et al., 2016	-0.1233	0.1127	0.88	[0.71; 1.10]	3.8%
Bozek et al., 2016	0.5630	0.1043	1.76	[1.43; 2.15]	3.9%
Dharmage et al., 2023	-0.0661	0.1143	0.94	[0.75; 1.17]	3.8%
Dharmage et al., 2023	0.5062	0.1468	1.66	[1.24; 2.21]	3.4%
Dharmage et al., 2023	0.0889	0.2595	1.09	[0.66; 1.82]	2.2%
Di Raimondo et al., 2020	1.2994	0.4841	3.67	[1.42; 9.47]	0.9%
Ferguson et al., 2014	0.8544	0.1828	2.35	[1.64; 3.36]	3.0%
Ferguson et al., 2014	0.7839	0.2452	2.19	[1.35; 3.53]	2.3%
Ferguson et al., 2014	1.2865	0.3030	3.62	[2.00; 6.56]	1.8%
Ferguson et al., 2014	0.5822	0.3352	1.79	[0.93; 3.46]	1.6%
Jo et al., 2015	0.5289	0.0819	1.70	[1.45; 1.99]	4.2%
Kaufmann et al., 2024	0.6831	0.0838	1.98	[1.68; 2.33]	4.2%
Kiani & Ahmadi, 2021	0.3293	0.1521	1.39	[1.03; 1.87]	3.3%
Kim et al., 2017	0.4824	0.1047	1.62	[1.32; 1.99]	3.9%
Lindberg et al., 2011	0.5110	0.1559	1.67	[1.23; 2.26]	3.3%
Lindberg et al., 2011	0.1765	0.1157	1.19	[0.95; 1.50]	3.8%
Lindberg et al., 2011	0.3307	0.1230	1.39	[1.09; 1.77]	3.7%
Mannino et al., 2008	0.5579	0.0446	1.75	[1.60; 1.91]	4.5%
Mannino et al., 2008	0.2601	0.0450	1.30	[1.19; 1.42]	4.5%
Mannino et al., 2008	0.4001	0.0505	1.49	[1.35; 1.65]	4.5%
Mannino et al., 2008	0.6951	0.0903	2.00	[1.68; 2.39]	4.1%
Mannino et al.2012	0.7641	0.0678	2.15	[1.88; 2.45]	4.3%
Mannino et al.2012	0.7036	0.0616	2.02	[1.79; 2.28]	4.4%
Methvin et al., 2009	1.1056	0.2826	3.02	[1.74; 5.26]	2.0%
Methvin et al., 2009	0.5110	0.4304	1.67	[0.72; 3.87]	1.1%
Methvin et al., 2009	0.5110	0.3247	1.67	[0.88; 3.15]	1.7%
Methvin et al., 2009	0.5110	0.4811	1.67	[0.65; 4.28]	0.9%
Park et al., 2015	0.6921	0.0507	2.00	[1.81; 2.21]	4.5%
Park et al., 2015	0.5977	0.0475	1.82	[1.66; 2.00]	4.5%
Sperandio et al., 2016	0.9666	0.4405	2.63	[1.11; 6.23]	1.1%
Yang et al., 2020	0.7129	0.0512	2.04	[1.84; 2.25]	4.5%
Random effects model			**1.70**	**[1.53; 1.88]**	**100.0%**



Heterogeneity: $I^2 = 84.2\%$, $\tau^2 = 0.0578$, $p < 0.0001$


Funnel Plot for the Studies with Crude OR
for Impaired lung function as the exposure and Hypertension as the outcome
Standard Error
0.0
0.1
0.2
0.3
0.4
0.5
-0.5
0.0
0.5
1.0
1.5
Effect Size (Log Odds Ratio)


Standardised treatment effect (z-score)
0
5
10
0
5
10
15
20
Inverse of standard error


Trim-and-Fill Funnel Plot
Standard Error
0.0
0.1
0.2
0.3
0.4
0.5
-0.5
0.0
0.5
1.0
1.5
Effect Size (Log Odds Ratio)


Study logOR SE(logOR) Odds Ratio OR 95%-CI Weight
Di Raimondo et al., 2020 1.2975 0.5491 3.66 [1.29; 11.10] 0.3%
Ferguson et al., 2014 0.4700 0.2958 1.60 [0.90; 2.87] 0.9%
Ferguson et al., 2014 1.0043 0.3850 2.73 [1.28; 5.79] 0.6%
Ferguson et al., 2014 -0.0408 0.4094 0.96 [0.43; 2.14] 0.5%
Jo et al., 2015 0.6098 0.1034 1.84 [1.50; 2.25] 2.3%
Kiani & Ahmadi, 2021 0.3577 0.1705 1.43 [1.02; 1.99] 1.7%
Kim et al., 2017 0.5365 0.1126 1.71 [1.37; 2.13] 2.2%
Kulbacka-Ortiz et al., 2022 0.6575 0.2216 1.93 [1.25; 2.98] 1.3%
Kulbacka-Ortiz et al., 2022 0.3507 0.1985 1.42 [0.96; 2.09] 1.5%
Kulbacka-Ortiz et al., 2022 0.0392 0.3229 1.04 [0.55; 1.95] 0.8%
Kulbacka-Ortiz et al., 2022 0.6098 0.2811 1.84 [1.06; 3.19] 1.0%
Kulbacka-Ortiz et al., 2022 0.2151 0.1622 1.24 [0.90; 1.70] 1.8%
Kulbacka-Ortiz et al., 2022 0.5766 0.1859 1.78 [1.24; 2.57] 1.6%
Kulbacka-Ortiz et al., 2022 0.1310 0.2429 1.14 [0.71; 1.84] 1.2%
Kulbacka-Ortiz et al., 2022 0.2700 0.2251 1.31 [0.84; 2.03] 1.3%
Kulbacka-Ortiz et al., 2022 0.4383 0.2348 1.55 [0.98; 2.46] 1.2%
Kulbacka-Ortiz et al., 2022 0.5822 0.2868 1.79 [1.02; 3.14] 0.9%
Kulbacka-Ortiz et al., 2022 0.1906 0.3252 1.21 [0.64; 2.29] 0.8%
Kulbacka-Ortiz et al., 2022 0.6523 0.3377 1.92 [0.99; 3.72] 0.7%
Kulbacka-Ortiz et al., 2022 0.6931 0.2273 2.00 [1.28; 3.12] 1.2%
Kulbacka-Ortiz et al., 2022 0.6627 0.2772 1.94 [1.13; 3.35] 1.0%
Kulbacka-Ortiz et al., 2022 0.5128 0.2275 1.67 [1.07; 2.61] 1.2%
Kulbacka-Ortiz et al., 2022 0.4637 0.3183 1.59 [0.85; 2.96] 0.8%
Kulbacka-Ortiz et al., 2022 0.3507 0.1489 1.42 [1.06; 1.90] 1.9%
Kulbacka-Ortiz et al., 2022 0.6575 0.2308 1.93 [1.23; 3.04] 1.2%
Kulbacka-Ortiz et al., 2022 0.4055 0.3537 1.50 [0.75; 3.00] 0.7%
Kulbacka-Ortiz et al., 2022 1.4207 0.4659 4.14 [1.66; 10.31] 0.4%
Kulbacka-Ortiz et al., 2022 0.3507 0.1958 1.42 [0.97; 2.09] 1.5%
Kulbacka-Ortiz et al., 2022 0.5128 0.2882 1.67 [0.95; 2.94] 0.9%
Kulbacka-Ortiz et al., 2022 0.3148 0.2084 1.37 [0.91; 2.06] 1.4%
Kulbacka-Ortiz et al., 2022 0.8459 0.2657 2.33 [1.38; 3.91] 1.0%
Kulbacka-Ortiz et al., 2022 0.1222 0.1960 1.13 [0.77; 1.66] 1.5%
Kulbacka-Ortiz et al., 2022 -0.1054 0.2329 0.90 [0.57; 1.42] 1.2%
Kulbacka-Ortiz et al., 2022 0.4824 0.2839 1.62 [0.93; 2.83] 0.9%
Kulbacka-Ortiz et al., 2022 0.1570 0.3471 1.17 [0.59; 2.30] 0.7%
Kulbacka-Ortiz et al., 2022 0.4318 0.3412 1.54 [0.79; 3.01] 0.7%
Kulbacka-Ortiz et al., 2022 0.4318 0.1230 1.54 [1.21; 1.96] 2.1%
Kulbacka-Ortiz et al., 2022 0.4447 0.3152 1.56 [0.84; 2.89] 0.8%
Kulbacka-Ortiz et al., 2022 0.2469 0.3377 1.28 [0.66; 2.48] 0.7%
Lindberg et al., 2011 0.3075 0.1675 1.36 [0.98; 1.89] 1.7%
Lindberg et al., 2011 0.2311 0.1241 1.26 [0.99; 1.61] 2.1%
Lindberg et al., 2011 0.3436 0.1019 1.41 [1.08; 1.61] 2.4%
Mannino et al., 2008 0.4055 0.0495 1.50 [1.40; 1.70] 2.8%
Mannino et al., 2008 0.0953 0.0734 1.10 [0.90; 1.20] 2.6%
Mannino et al., 2008 0.3365 0.0530 1.40 [1.30; 1.60] 2.8%
Mannino et al., 2008 0.4700 0.0968 1.60 [1.30; 1.90] 2.4%
Mannino et al.2012 0.7324 0.0745 2.08 [1.80; 2.41] 2.6%
Mannino et al.2012 0.3646 0.0708 1.44 [1.25; 1.65] 2.7%
Methvin et al., 2009 0.9933 0.3347 2.70 [1.40; 5.20] 0.7%
Methvin et al., 2009 0.1823 0.5533 1.20 [0.40; 3.50] 0.3%
Methvin et al., 2009 0.4700 0.3765 1.60 [0.80; 3.50] 0.6%
Methvin et al., 2009 0.4700 0.5083 1.60 [0.60; 4.40] 0.4%
Sperandio et al., 2016 2.8629 1.2024 17.51 [1.66; 184.82] 0.1%
Triest et al., 2019 -0.2614 0.3453 0.77 [0.39; 1.51] 0.7%
Triest et al., 2019 0.9203 0.3212 2.51 [1.34; 4.72] 0.8%
Triest et al., 2019 -0.0101 0.2818 0.99 [0.57; 1.72] 0.9%
Triest et al., 2019 -1.1087 0.6671 0.33 [0.09; 1.23] 0.2%
Triest et al., 2019 -0.2744 0.2125 0.76 [0.50; 1.15] 1.3%
Triest et al., 2019 0.2927 0.2748 1.34 [0.78; 2.29] 1.0%
Triest et al., 2019 -0.0101 0.3910 0.99 [0.46; 2.13] 0.6%
Triest et al., 2019 -0.1508 0.3196 0.86 [0.46; 1.61] 0.8%
Triest et al., 2019 0.0392 0.2477 1.04 [0.64; 1.69] 1.1%
Triest et al., 2019 0.2624 0.4595 1.30 [0.53; 3.21] 0.4%
Triest et al., 2019 0.4253 0.3277 1.53 [0.80; 2.89] 0.8%
Triest et al., 2019 -0.2877 0.3059 0.75 [0.41; 1.36] 0.8%
Triest et al., 2019 -0.0408 0.2911 0.96 [0.54; 1.69] 0.9%
Triest et al., 2019 0.0770 0.0938 1.08 [0.90; 1.30] 2.4%
Triest et al., 2019 -0.4308 0.2712 0.65 [0.38; 1.10] 1.0%
Triest et al., 2019 0.5933 0.2672 1.81 [1.07; 3.05] 1.0%
Triest et al., 2019 0.1222 0.2751 1.13 [0.66; 1.94] 1.0%
Triest et al., 2019 -0.4155 0.5168 0.66 [0.24; 1.82] 0.4%
Triest et al., 2019 -0.1393 0.5065 0.87 [0.32; 2.33] 0.4%
Triest et al., 2019 0.9517 0.5737 2.59 [0.84; 7.96] 0.3%
Triest et al., 2019 0.2311 0.0869 1.26 [1.06; 1.49] 2.5%
Triest et al., 2019 -0.1985 0.3786 0.82 [0.39; 1.72] 0.6%
Triest et al., 2019 -0.3011 0.5096 0.74 [0.27; 1.99] 0.4%
Triest et al., 2019 0.3221 0.2739 1.38 [0.81; 2.37] 1.0%
Triest et al., 2019 0.3293 0.5324 1.39 [0.49; 3.95] 0.3%
Triest et al., 2019 0.1398 0.1847 1.15 [0.80; 1.65] 1.6%
Triest et al., 2019 0.8459 0.2796 2.33 [1.35; 4.04] 1.0%
Triest et al., 2019 -0.6349 0.4236 0.53 [0.23; 1.21] 0.5%
Triest et al., 2019 -0.2744 0.3956 0.76 [0.35; 1.65] 0.6%
Triest et al., 2019 1.0953 0.2106 2.99 [1.98; 4.52] 1.4%
Triest et al., 2019 0.1044 0.3410 1.11 [0.57; 2.17] 0.7%
Triest et al., 2019 0.2311 0.2873 1.26 [0.72; 2.22] 0.9%
Yang et al., 2020 0.1044 0.0436 1.11 [1.02; 1.21] 2.9%
Random effects model 1.40 [1.31; 1.49] 100.0%
0.5 1 1.5 2 3 4 5
Heterogeneity: I^2 = 59.8%, τ^2 = 0.0362, p < 0.0001


Funnel Plot for the Studies with Adjusted OR
for Impaired lung function as the exposure and Hypertension as the outcome
Standard Error
0
10
20
30
40
-1
0
1
2
3
Effect Size (Log Odds Ratio)


Standardised treatment effect (z-score)
4
2
0
-2
-4
0
5
10
15
20
Inverse of standard error


Trim-and-Fill Funnel Plot
Standard Error
0
10
20
30
40
-3
-2
-1
0
1
2
3
Effect Size (Log Odds Ratio)


Study
logOR
SE(logOR)
Odds Ratio
OR
95%-CI
Weight
Birhan & Abebe, 2018 3.4500 1.0437 31.50 [4.07; 243.62] 3.6%
Femi-Adeoye et al., 2024 1.1820 0.6061 3.26 [0.99; 10.69] 6.4%
Femi-Adeoye et al., 2024 0.4581 0.3515 1.58 [0.79; 3.15] 8.7%
Femi-Adeoye et al., 2024 0.6345 0.3168 1.89 [1.01; 3.51] 9.0%
Ferrari et al., 2019 -0.2083 0.1287 0.81 [0.63; 1.04] 10.4%
Kim et al., 2021 0.8713 0.2563 2.39 [1.45; 3.96] 9.5%
Lee et al., 2020 0.6627 0.2304 1.94 [1.24; 3.06] 9.7%
Patil et al., 2012 2.0849 0.7870 8.04 [1.72; 37.61] 5.0%
Taneda et al., 2004 1.4171 0.2899 4.12 [2.34; 7.28] 9.3%
Taneda et al., 2004 1.1669 0.2002 3.21 [2.17; 4.75] 10.0%
Utsugi et al., 2016 0.4855 0.2145 1.62 [1.07; 2.47] 9.9%
Yadav et al., 2015 4.8903 1.2744 133.00 [10.94; 1616.71] 2.7%
Yadav et al., 2015 1.8507 1.1672 6.36 [0.65; 62.70] 3.1%
Yadav et al., 2015 3.1499 1.2669 23.33 [1.95; 279.44] 2.7%
Random effects model 3.00 [1.86; 4.82] 100.0%
0.5
1
1.5
2
3
4
8
10
Heterogeneity: I^2 = 84.7%, τ^2 = 0.5489, p < 0.0001


Standard Error
0.0
0.2
0.4
0.6
0.8
1.0
1.2
-1
0
1
2
3
4
5
Effect Size (Log Odds Ratio)


Standardised treatment effect (z-score)
6
4
2
0
-2
0
2
4
6
8
Inverse of standard error


Trim-and-Fill Funnel Plot
Standard Error
0.0
0.2
0.4
0.6
0.8
1.0
1.2
-6
-4
-2
0
2
4
6
Effect Size (Log Odds Ratio)


Study
logOR
SE(logOR)
Odds Ratio
OR
95%-CI
Weight
Femi-Adeoye et al., 2024 1.0969 0.4471 3.00 [1.24; 7.17] 8.2%
Kim et al., 2021 0.7419 0.3189 2.10 [1.12; 3.91] 16.1%
Lee et al., 2020 0.3716 0.2398 1.45 [0.91; 2.33] 28.5%
Taneda et al., 2004 0.8286 0.3247 2.29 [1.21; 4.32] 15.5%
Taneda et al., 2004 0.6931 0.2273 2.00 [1.28; 3.12] 31.7%
Utsugi et al., 2016 0.0000 . 1.00 0.0%
Random effects model 1.94 [1.51; 2.50] 100.0%
0.5
1
1.5
2
3
4
5
Heterogeneity: I^2 = 0.0%, τ^2 = 0, p = 0.5992


Standard Error
0.0
0.5
1.0
1.5
-3
-2
-1
0
1
2
3
4
Effect Size (Log Odds Ratio)


Trim-and-Fill Funnel Plot
Standard Error
0.0
0.5
1.0
1.5
-3
-2
-1
0
1
2
3
4
Effect Size (Log Odds Ratio)


Leave-One-Out Sensitivity Analysis
Yang et al., 2020
Sperandio et al., 2016
Park et al., 2015
Methvin et al., 2009
Mannino et al.2012
Mannino et al., 2008
Lindberg et al., 2011
Kim et al., 2017
Kiani & Ahmadi, 2021
Kaufmann et al., 2024
Jo et al., 2015
Ferguson et al., 2014
Di Raimondo et al., 2020
Dharmage et al., 2023
Bozek et al., 2016
Excluded Study
1.5
1.6
1.7
1.8
1.9
Pooled Effect Size (OR)
Blue points: Effect size with 95% CI. Red dashed line: Original pooled effect.


Leave-One-Out Sensitivity Analysis
Yang et al., 2020
Triest et al., 2019
Sperandio et al., 2016
Methvin et al., 2009
Mannino et al.2012
Mannino et al., 2008
Lindberg et al., 2011
Kulbacka-Ortiz et al., 2022
Kim et al., 2017
Kiani & Ahmadi, 2021
Jo et al., 2015
Ferguson et al., 2014
Di Raimondo et al., 2020
Excluded Study
1.30
1.35
1.40
1.45
1.50
Pooled Effect Size (OR)
Blue points: Effect size with 95% CI. Red dashed line: Original pooled effect.


Leave-One-Out Sensitivity Analysis
Yadav et al., 2015
Utsugi et al., 2016
Taneda et al., 2004
Patil et al., 2012
Lee et al., 2020
Kim et al., 2021
Ferrari et al., 2019
Femi-Adeoye et al., 2024
Birhan & Abebe, 2018
Excluded Study
2
3
4
5
Pooled Effect Size (OR)
Blue points: Effect size with 95% CI. Red dashed line: Original pooled effect.


Study
logOR
SE(logOR)
Odds Ratio
OR
95%-CI
Weight
Study_Design = Case-Control Study
Bozek et al., 2016 -0.1233 0.1127 0.88 [0.71; 1.10] 3.8%
Bozek et al., 2016 0.5630 0.1043 1.76 [1.43; 2.15] 3.9%
Di Raimondo et al., 2020 1.2994 0.4841 3.67 [1.42; 9.47] 0.9%
Random effects model 1.61 [0.77; 3.35] 8.7%
Heterogeneity: I^2 = 91.9%, τ^2 = 0.3550, p < 0.0001
Study_Design = Cross-Sectional Study
Dharmage et al., 2023 -0.0661 0.1143 0.94 [0.75; 1.17] 3.8%
Dharmage et al., 2023 0.5062 0.1468 1.66 [1.24; 2.21] 3.4%
Dharmage et al., 2023 0.0889 0.2595 1.09 [0.66; 1.82] 2.2%
Ferguson et al., 2014 0.8544 0.1828 2.35 [1.64; 3.36] 3.0%
Ferguson et al., 2014 0.7839 0.2452 2.19 [1.35; 3.53] 2.3%
Ferguson et al., 2014 1.2865 0.3030 3.62 [2.00; 6.56] 1.8%
Ferguson et al., 2014 0.5822 0.3352 1.79 [0.93; 3.46] 1.6%
Jo et al., 2015 0.5289 0.0819 1.70 [1.45; 1.99] 4.2%
Kaufmann et al., 2024 0.6831 0.0838 1.98 [1.68; 2.33] 4.2%
Kiani & Ahmadi, 2021 0.3293 0.1521 1.39 [1.03; 1.87] 3.3%
Kim et al., 2017 0.4824 0.1047 1.62 [1.32; 1.99] 3.9%
Lindberg et al., 2011 0.5110 0.1559 1.67 [1.23; 2.26] 3.3%
Lindberg et al., 2011 0.1765 0.1157 1.19 [0.95; 1.50] 3.8%
Lindberg et al., 2011 0.3307 0.1230 1.39 [1.09; 1.77] 3.7%
Mannino et al.2012 0.7641 0.0678 2.15 [1.88; 2.45] 4.3%
Mannino et al.2012 0.7036 0.0616 2.02 [1.79; 2.28] 4.4%
Methvin et al., 2009 1.1056 0.2826 3.02 [1.74; 5.26] 2.0%
Methvin et al., 2009 0.5110 0.4304 1.67 [0.72; 3.87] 1.1%
Methvin et al., 2009 0.5110 0.3247 1.67 [0.88; 3.15] 1.7%
Methvin et al., 2009 0.5110 0.4811 1.67 [0.65; 4.28] 0.9%
Park et al., 2015 0.6921 0.0507 2.00 [1.81; 2.21] 4.5%
Park et al., 2015 0.5977 0.0475 1.82 [1.66; 2.00] 4.5%
Sperandio et al., 2016 0.9666 0.4405 2.63 [1.11; 6.23] 1.1%
Yang et al., 2020 0.7129 0.0512 2.04 [1.84; 2.25] 4.5%
Random effects model 1.75 [1.57; 1.96] 73.6%
Heterogeneity: I^2 = 74.8%, τ^2 = 0.0483, p < 0.0001
Study_Design = Cohort Study
Mannino et al., 2008 0.5579 0.0446 1.75 [1.60; 1.91] 4.5%
Mannino et al., 2008 0.2601 0.0450 1.30 [1.19; 1.42] 4.5%
Mannino et al., 2008 0.4001 0.0505 1.49 [1.35; 1.65] 4.5%
Mannino et al., 2008 0.6951 0.0903 2.00 [1.68; 2.39] 4.1%
Random effects model 1.60 [1.34; 1.91] 17.7%
Heterogeneity: I^2 = 90.5%, τ^2 = 0.0302, p < 0.0001
Random effects model 1.70 [1.53; 1.88] 100.0%
0.5
1
1.5
2
3
4
8
10
Heterogeneity: I^2 = 84.2%, τ^2 = 0.0578, p < 0.0001
Test for subgroup differences: χ^2_2 = 0.77, df = 2 (p = 0.6820)


Study
logOR
SE(logOR)
Odds Ratio
OR
95%-CI
Weight
Country = Poland
Bozek et al., 2016 -0.1233 0.1127 0.88 [0.71; 1.10] 3.8%
Bozek et al., 2016 0.5630 0.1043 1.76 [1.43; 2.15] 3.9%
Random effects model 1.25 [0.64; 2.44] 7.8%
Heterogeneity: I^2 = 95%, τ^2 = 0.2237, p < 0.0001
Country = Australia
Dharmage et al., 2023 -0.0661 0.1143 0.94 [0.75; 1.17] 3.8%
Dharmage et al., 2023 0.5062 0.1468 1.66 [1.24; 2.21] 3.4%
Dharmage et al., 2023 0.0889 0.2595 1.09 [0.66; 1.82] 2.2%
Random effects model 1.19 [0.82; 1.73] 9.4%
Heterogeneity: I^2 = 79%, τ^2 = 0.0788, p = 0.0086
Country = Italy
Di Raimondo et al., 2020 1.2994 0.4841 3.67 [1.42; 9.47] 0.9%
Country = United States
Ferguson et al., 2014 0.8544 0.1828 2.35 [1.64; 3.36] 3.0%
Ferguson et al., 2014 0.7839 0.2452 2.19 [1.35; 3.53] 2.3%
Ferguson et al., 2014 1.2865 0.3030 3.62 [2.00; 6.56] 1.8%
Ferguson et al., 2014 0.5822 0.3352 1.79 [0.93; 3.46] 1.6%
Mannino et al., 2008 0.5579 0.0446 1.75 [1.60; 1.91] 4.5%
Mannino et al., 2008 0.2601 0.0450 1.30 [1.19; 1.42] 4.5%
Mannino et al., 2008 0.4001 0.0505 1.49 [1.35; 1.65] 4.5%
Mannino et al., 2008 0.6951 0.0903 2.00 [1.68; 2.39] 4.1%
Methvin et al., 2009 1.1056 0.2826 3.02 [1.74; 5.26] 2.0%
Methvin et al., 2009 0.5110 0.4304 1.67 [0.72; 3.87] 1.1%
Methvin et al., 2009 0.5110 0.3247 1.67 [0.88; 3.15] 1.7%
Methvin et al., 2009 0.5110 0.4811 1.67 [0.65; 4.28] 0.9%
Yang et al., 2020 0.7129 0.0512 2.04 [1.84; 2.25] 4.5%
Random effects model 1.87 [1.61; 2.18] 36.5%
Heterogeneity: I^2 = 83.4%, τ^2 = 0.0428, p < 0.0001
Country = Korea
Jo et al., 2015 0.5289 0.0819 1.70 [1.45; 1.99] 4.2%
Kim et al., 2017 0.4824 0.1047 1.62 [1.32; 1.99] 3.9%
Park et al., 2015 0.6921 0.0507 2.00 [1.81; 2.21] 4.5%
Park et al., 2015 0.5977 0.0475 1.82 [1.66; 2.00] 4.5%
Random effects model 1.82 [1.67; 1.98] 17.2%
Heterogeneity: I^2 = 41.7%, τ^2 = 0.0031, p = 0.1613
Country = Austria
Kaufmann et al., 2024 0.6831 0.0838 1.98 [1.68; 2.33] 4.2%
Country = Iran
Kiani & Ahmadi, 2021 0.3293 0.1521 1.39 [1.03; 1.87] 3.3%
Country = Sweden
Lindberg et al., 2011 0.5110 0.1559 1.67 [1.23; 2.26] 3.3%
Lindberg et al., 2011 0.1765 0.1157 1.19 [0.95; 1.50] 3.8%
Lindberg et al., 2011 0.3307 0.1230 1.39 [1.09; 1.77] 3.7%
Random effects model 1.37 [1.15; 1.64] 10.8%
Heterogeneity: I^2 = 33.8%, τ^2 = 0.0080, p = 0.2209
Country = Selected Countries
Mannino et al.2012 0.7641 0.0678 2.15 [1.88; 2.45] 4.3%
Mannino et al.2012 0.7036 0.0616 2.02 [1.79; 2.28] 4.4%
Random effects model 2.08 [1.90; 2.27] 8.8%
Heterogeneity: I^2 = 0%, τ^2 = 0, p = 0.5089
Country = Brazil
Sperandio et al., 2016 0.9666 0.4405 2.63 [1.11; 6.23] 1.1%
Random effects model 1.70 [1.53; 1.88] 100.0%
0.5
1
1.5
2
3
4
8
10
Heterogeneity: I^2 = 84.2%, τ^2 = 0.0578, p < 0.0001
Test for subgroup differences: χ^2_{Ω} = 30.73, df = 9 (p = 0.0003)


Study
logOR
SE(logOR)
Odds Ratio
OR
95%-CI
Weight
Lung_Function_Impairement_Type = Obstructive
Bozek et al., 2016 -0.1233 0.1127 0.88 [0.71; 1.10] 3.8%
Bozek et al., 2016 0.5630 0.1043 1.76 [1.43; 2.15] 3.9%
Dharmage et al., 2023 -0.0661 0.1143 0.94 [0.75; 1.17] 3.8%
Di Raimondo et al., 2020 1.2994 0.4841 3.67 [1.42; 9.47] 0.9%
Ferguson et al., 2014 0.8544 0.1828 2.35 [1.64; 3.36] 3.0%
Ferguson et al., 2014 0.7839 0.2452 2.19 [1.35; 3.53] 2.3%
Ferguson et al., 2014 1.2865 0.3030 3.62 [2.00; 6.56] 1.8%
Ferguson et al., 2014 0.5822 0.3352 1.79 [0.93; 3.46] 1.6%
Jo et al., 2015 0.5289 0.0819 1.70 [1.45; 1.99] 4.2%
Kaufmann et al., 2024 0.6831 0.0838 1.98 [1.68; 2.33] 4.2%
Kiani & Ahmadi, 2021 0.3293 0.1521 1.39 [1.03; 1.87] 3.3%
Kim et al., 2017 0.4824 0.1047 1.62 [1.32; 1.99] 3.9%
Lindberg et al., 2011 0.1765 0.1157 1.19 [0.95; 1.50] 3.8%
Lindberg et al., 2011 0.3307 0.1230 1.39 [1.09; 1.77] 3.7%
Mannino et al., 2008 0.2601 0.0450 1.30 [1.19; 1.42] 4.5%
Mannino et al., 2008 0.4001 0.0505 1.49 [1.35; 1.65] 4.5%
Mannino et al., 2008 0.6951 0.0903 2.00 [1.68; 2.39] 4.1%
Mannino et al.2012 0.7036 0.0616 2.02 [1.79; 2.28] 4.4%
Methvin et al., 2009 0.5110 0.4304 1.67 [0.72; 3.87] 1.1%
Methvin et al., 2009 0.5110 0.3247 1.67 [0.88; 3.15] 1.7%
Methvin et al., 2009 0.5110 0.4811 1.67 [0.65; 4.28] 0.9%
Park et al., 2015 0.5977 0.0475 1.82 [1.66; 2.00] 4.5%
Yang et al., 2020 0.7129 0.0512 2.04 [1.84; 2.25] 4.5%
Random effects model 1.65 [1.45; 1.86] 74.7%
Heterogeneity: I^2 = 85.8%, τ^2 = 0.0666, p < 0.0001
Lung_Function_Impairement_Type = Restrictive
Dharmage et al., 2023 0.5062 0.1468 1.66 [1.24; 2.21] 3.4%
Lindberg et al., 2011 0.5110 0.1559 1.67 [1.23; 2.26] 3.3%
Mannino et al., 2008 0.5579 0.0446 1.75 [1.60; 1.91] 4.5%
Mannino et al.2012 0.7641 0.0678 2.15 [1.88; 2.45] 4.3%
Methvin et al., 2009 1.1056 0.2826 3.02 [1.74; 5.26] 2.0%
Park et al., 2015 0.6921 0.0507 2.00 [1.81; 2.21] 4.5%
Sperandio et al., 2016 0.9666 0.4405 2.63 [1.11; 6.23] 1.1%
Random effects model 1.92 [1.74; 2.12] 23.1%
Heterogeneity: I^2 = 52.2%, τ^2 = 0.0069, p = 0.0505
Lung_Function_Impairement_Type = Mixed
Dharmage et al., 2023 0.0889 0.2595 1.09 [0.66; 1.82] 2.2%
Random effects model 1.70 [1.53; 1.88] 100.0%
0.5
1
1.5
2
3
4
8
10
Heterogeneity: I^2 = 84.2%, τ^2 = 0.0578, p < 0.0001
Test for subgroup differences: χ^2_2 = 7.32, df = 2 (p = 0.0257)


Study logOR SE(logOR) Odds Ratio OR 95%-CI Weight
Study_Design = Case-Control Study
Di Raimondo et al., 2020 1.2975 0.5491 3.66 [1.29; 11.10] 0.3%
Study_Design = Cross-Sectional Study
Ferguson et al., 2014 0.4700 0.2958 1.60 [0.90; 2.87] 0.9%
Ferguson et al., 2014 1.0043 0.3850 2.73 [1.28; 5.79] 0.6%
Ferguson et al., 2014 -0.0408 0.4094 0.96 [0.43; 2.14] 0.5%
Jo et al., 2015 0.6098 0.1034 1.84 [1.50; 2.25] 2.3%
Kiani & Ahmadi, 2021 0.3577 0.1705 1.43 [1.02; 1.99] 1.7%
Kim et al., 2017 0.5365 0.1126 1.71 [1.37; 2.13] 2.2%
Kulbacka-Ortiz et al., 2022 0.6575 0.2216 1.93 [1.25; 2.98] 1.3%
Kulbacka-Ortiz et al., 2022 0.3507 0.1985 1.42 [0.96; 2.09] 1.5%
Kulbacka-Ortiz et al., 2022 0.0392 0.3229 1.04 [0.55; 1.95] 0.8%
Kulbacka-Ortiz et al., 2022 0.6098 0.2811 1.84 [1.06; 3.19] 1.0%
Kulbacka-Ortiz et al., 2022 0.2151 0.1622 1.24 [0.90; 1.70] 1.8%
Kulbacka-Ortiz et al., 2022 0.5766 0.1859 1.78 [1.24; 2.57] 1.6%
Kulbacka-Ortiz et al., 2022 0.1310 0.2429 1.14 [0.71; 1.84] 1.2%
Kulbacka-Ortiz et al., 2022 0.2700 0.2251 1.31 [0.84; 2.03] 1.3%
Kulbacka-Ortiz et al., 2022 0.4383 0.2348 1.55 [0.98; 2.46] 1.2%
Kulbacka-Ortiz et al., 2022 0.5822 0.2868 1.79 [1.02; 3.14] 0.9%
Kulbacka-Ortiz et al., 2022 0.1906 0.3252 1.21 [0.64; 2.29] 0.8%
Kulbacka-Ortiz et al., 2022 0.6523 0.3377 1.92 [0.99; 3.72] 0.7%
Kulbacka-Ortiz et al., 2022 0.6931 0.2273 2.00 [1.28; 3.12] 1.2%
Kulbacka-Ortiz et al., 2022 0.6627 0.2772 1.94 [1.13; 3.35] 1.0%
Kulbacka-Ortiz et al., 2022 0.5128 0.2275 1.67 [1.07; 2.61] 1.2%
Kulbacka-Ortiz et al., 2022 0.4637 0.3183 1.59 [0.85; 2.96] 0.8%
Kulbacka-Ortiz et al., 2022 0.3507 0.1489 1.42 [1.06; 1.90] 1.9%
Kulbacka-Ortiz et al., 2022 0.6575 0.2308 1.93 [1.23; 3.04] 1.2%
Kulbacka-Ortiz et al., 2022 0.4055 0.3537 1.50 [0.75; 3.00] 0.7%
Kulbacka-Ortiz et al., 2022 1.4207 0.4659 4.14 [1.66; 10.31] 0.4%
Kulbacka-Ortiz et al., 2022 0.3507 0.1958 1.42 [0.97; 2.09] 1.5%
Kulbacka-Ortiz et al., 2022 0.5128 0.2882 1.67 [0.95; 2.94] 0.9%
Kulbacka-Ortiz et al., 2022 0.3148 0.2084 1.37 [0.91; 2.06] 1.4%
Kulbacka-Ortiz et al., 2022 0.8459 0.2657 2.33 [1.38; 3.91] 1.0%
Kulbacka-Ortiz et al., 2022 0.1222 0.1960 1.13 [0.77; 1.66] 1.5%
Kulbacka-Ortiz et al., 2022 -0.1054 0.2329 0.90 [0.57; 1.42] 1.2%
Kulbacka-Ortiz et al., 2022 0.4824 0.2839 1.62 [0.93; 2.83] 0.9%
Kulbacka-Ortiz et al., 2022 0.1570 0.3471 1.17 [0.59; 2.30] 0.7%
Kulbacka-Ortiz et al., 2022 0.4318 0.3412 1.54 [0.79; 3.01] 0.7%
Kulbacka-Ortiz et al., 2022 0.4318 0.1230 1.54 [1.21; 1.96] 2.1%
Kulbacka-Ortiz et al., 2022 0.4447 0.3152 1.56 [0.84; 2.89] 0.8%
Kulbacka-Ortiz et al., 2022 0.2469 0.3377 1.28 [0.66; 2.48] 0.7%
Lindberg et al., 2011 0.3075 0.1675 1.36 [0.98; 1.89] 1.7%
Lindberg et al., 2011 0.2311 0.1241 1.26 [0.99; 1.61] 2.1%
Lindberg et al., 2011 0.3436 0.1019 1.41 [1.08; 1.61] 2.4%
Mannino et al.2012 0.7324 0.0745 2.08 [1.80; 2.41] 2.6%
Mannino et al.2012 0.3646 0.0708 1.44 [1.25; 1.65] 2.7%
Methvin et al., 2009 0.9933 0.3347 2.70 [1.40; 5.20] 0.7%
Methvin et al., 2009 0.1823 0.5533 1.20 [0.40; 3.50] 0.3%
Methvin et al., 2009 0.4700 0.3765 1.60 [0.80; 3.50] 0.6%
Methvin et al., 2009 0.4700 0.5083 1.60 [0.60; 4.40] 0.4%
Sperandio et al., 2016 2.8629 1.2024 17.51 [1.66; 184.82] 0.1%
Triest et al., 2019 -0.2614 0.3453 0.77 [0.39; 1.51] 0.7%
Triest et al., 2019 0.9203 0.3212 2.51 [1.34; 4.72] 0.8%
Triest et al., 2019 -0.0101 0.2818 0.99 [0.57; 1.72] 0.9%
Triest et al., 2019 -1.1087 0.6671 0.33 [0.09; 1.23] 0.2%
Triest et al., 2019 -0.2744 0.2125 0.76 [0.50; 1.15] 1.3%
Triest et al., 2019 0.2927 0.2748 1.34 [0.78; 2.29] 1.0%
Triest et al., 2019 -0.0101 0.3910 0.99 [0.46; 2.13] 0.6%
Triest et al., 2019 -0.1508 0.3196 0.86 [0.46; 1.61] 0.8%
Triest et al., 2019 0.0392 0.2477 1.04 [0.64; 1.69] 1.1%
Triest et al., 2019 0.2624 0.4595 1.30 [0.53; 3.21] 0.4%
Triest et al., 2019 0.4253 0.3277 1.53 [0.80; 2.89] 0.8%
Triest et al., 2019 -0.2877 0.3059 0.75 [0.41; 1.36] 0.8%
Triest et al., 2019 -0.0408 0.2911 0.96 [0.54; 1.69] 0.9%
Triest et al., 2019 0.0770 0.0938 1.08 [0.90; 1.30] 2.4%
Triest et al., 2019 -0.4308 0.2712 0.65 [0.38; 1.10] 1.0%
Triest et al., 2019 0.5933 0.2672 1.81 [1.07; 3.05] 1.0%
Triest et al., 2019 0.1222 0.2751 1.13 [0.66; 1.94] 1.0%
Triest et al., 2019 -0.4155 0.5168 0.66 [0.24; 1.82] 0.4%
Triest et al., 2019 -0.1393 0.5065 0.87 [0.32; 2.33] 0.4%
Triest et al., 2019 0.9517 0.5737 2.59 [0.84; 7.96] 0.3%
Triest et al., 2019 0.2311 0.0869 1.26 [1.06; 1.49] 2.5%
Triest et al., 2019 -0.1985 0.3786 0.82 [0.39; 1.72] 0.6%
Triest et al., 2019 -0.3011 0.5096 0.74 [0.27; 1.99] 0.4%
Triest et al., 2019 0.3221 0.2739 1.38 [0.81; 2.37] 1.0%
Triest et al., 2019 0.3293 0.5324 1.39 [0.49; 3.95] 0.3%
Triest et al., 2019 0.1398 0.1847 1.15 [0.80; 1.65] 1.6%
Triest et al., 2019 0.8459 0.2796 2.33 [1.35; 4.04] 1.0%
Triest et al., 2019 -0.6349 0.4236 0.53 [0.23; 1.21] 0.5%
Triest et al., 2019 -0.2744 0.3956 0.76 [0.35; 1.65] 0.6%
Triest et al., 2019 1.0953 0.2106 2.99 [1.98; 4.52] 1.4%
Triest et al., 2019 0.1044 0.3410 1.11 [0.57; 2.17] 0.7%
Triest et al., 2019 0.2311 0.2873 1.26 [0.72; 2.22] 0.9%
Yang et al., 2020 0.1044 0.0436 1.11 [1.02; 1.21] 2.9%
Random effects model 1.39 [1.30; 1.50] 89.0%
Heterogeneity: I^2 = 58.7%, τ^2 = 0.0410, p < 0.0001
Study_Design = Cohort Study
Mannino et al., 2008 0.4055 0.0495 1.50 [1.40; 1.70] 2.8%
Mannino et al., 2008 0.0953 0.0734 1.10 [0.90; 1.20] 2.6%
Mannino et al., 2008 0.3365 0.0530 1.40 [1.30; 1.60] 2.8%
Mannino et al., 2008 0.4700 0.0968 1.60 [1.30; 1.90] 2.4%
Random effects model 1.38 [1.19; 1.61] 10.7%
Heterogeneity: I^2 = 79.5%, τ^2 = 0.0196, p = 0.0022
Random effects model 1.40 [1.31; 1.49] 100.0%
0.5 1 1.5 2 3 4
Heterogeneity: I^2 = 59.8%, τ^2 = 0.0362, p < 0.0001
Test for subgroup differences: χ^2_2 = 3.09, df = 2 (p = 0.2128)


Study
logOR
SE(logOR)
Odds Ratio
OR
95%-CI
Weight
Lung_Function_Impairement_Type = Obstructive
Di Raimondo et al., 2020 1.2975 0.5491 3.66 [1.29; 11.10] 0.3%
Ferguson et al., 2014 0.4700 0.2958 1.60 [0.90; 2.87] 0.9%
Ferguson et al., 2014 1.0043 0.3850 2.73 [1.28; 5.79] 0.6%
Ferguson et al., 2014 -0.0408 0.4094 0.96 [0.43; 2.14] 0.5%
Jo et al., 2015 0.6098 0.1034 1.84 [1.50; 2.25] 2.3%
Kiani & Ahmadi, 2021 0.3577 0.1705 1.43 [1.02; 1.99] 1.7%
Kim et al., 2017 0.5365 0.1126 1.71 [1.37; 2.13] 2.2%
Lindberg et al., 2011 0.2311 0.1241 1.26 [0.99; 1.61] 2.1%
Lindberg et al., 2011 0.3436 0.1019 1.41 [1.08; 1.61] 2.4%
Mannino et al., 2008 0.0953 0.0734 1.10 [0.90; 1.20] 2.6%
Mannino et al., 2008 0.3365 0.0530 1.40 [1.30; 1.60] 2.8%
Mannino et al., 2008 0.4700 0.0968 1.60 [1.30; 1.90] 2.4%
Mannino et al.2012 0.3646 0.0708 1.44 [1.25; 1.65] 2.7%
Methvin et al., 2009 0.1823 0.5533 1.20 [0.40; 3.50] 0.3%
Methvin et al., 2009 0.4700 0.3765 1.60 [0.80; 3.50] 0.6%
Methvin et al., 2009 0.4700 0.5083 1.60 [0.60; 4.40] 0.4%
Triest et al., 2019 -0.2614 0.3453 0.77 [0.39; 1.51] 0.7%
Triest et al., 2019 0.9203 0.3212 2.51 [1.34; 4.72] 0.8%
Triest et al., 2019 -0.0101 0.2818 0.99 [0.57; 1.72] 0.9%
Triest et al., 2019 -1.1087 0.6671 0.33 [0.09; 1.23] 0.2%
Triest et al., 2019 -0.2744 0.2125 0.76 [0.50; 1.15] 1.3%
Triest et al., 2019 0.2927 0.2748 1.34 [0.78; 2.29] 1.0%
Triest et al., 2019 -0.0101 0.3910 0.99 [0.46; 2.13] 0.6%
Triest et al., 2019 -0.1508 0.3196 0.86 [0.46; 1.61] 0.8%
Triest et al., 2019 0.0392 0.2477 1.04 [0.64; 1.69] 1.1%
Triest et al., 2019 0.2624 0.4595 1.30 [0.53; 3.21] 0.4%
Triest et al., 2019 0.4253 0.3277 1.53 [0.80; 2.89] 0.8%
Triest et al., 2019 -0.2877 0.3059 0.75 [0.41; 1.36] 0.8%
Triest et al., 2019 -0.0408 0.2911 0.96 [0.54; 1.69] 0.9%
Triest et al., 2019 0.0770 0.0938 1.08 [0.90; 1.30] 2.4%
Triest et al., 2019 -0.4308 0.2712 0.65 [0.38; 1.10] 1.0%
Triest et al., 2019 0.5933 0.2672 1.81 [1.07; 3.05] 1.0%
Triest et al., 2019 0.1222 0.2751 1.13 [0.66; 1.94] 1.0%
Triest et al., 2019 -0.4155 0.5168 0.66 [0.24; 1.82] 0.4%
Triest et al., 2019 -0.1393 0.5065 0.87 [0.32; 2.33] 0.4%
Triest et al., 2019 0.9517 0.5737 2.59 [0.84; 7.96] 0.3%
Triest et al., 2019 0.2311 0.0869 1.26 [1.06; 1.49] 2.5%
Triest et al., 2019 -0.1985 0.3786 0.82 [0.39; 1.72] 0.6%
Triest et al., 2019 -0.3011 0.5096 0.74 [0.27; 1.99] 0.4%
Triest et al., 2019 0.3221 0.2739 1.38 [0.81; 2.37] 1.0%
Triest et al., 2019 0.3293 0.5324 1.39 [0.49; 3.95] 0.3%
Triest et al., 2019 0.1398 0.1847 1.15 [0.80; 1.65] 1.6%
Triest et al., 2019 0.8459 0.2796 2.33 [1.35; 4.04] 1.0%
Triest et al., 2019 -0.6349 0.4236 0.53 [0.23; 1.21] 0.5%
Triest et al., 2019 -0.2744 0.3956 0.76 [0.35; 1.65] 0.6%
Triest et al., 2019 1.0953 0.2106 2.99 [1.98; 4.52] 1.4%
Triest et al., 2019 0.1044 0.3410 1.11 [0.57; 2.17] 0.7%
Triest et al., 2019 0.2311 0.2873 1.26 [0.72; 2.22] 0.9%
Yang et al., 2020 0.1044 0.0436 1.11 [1.02; 1.21] 2.9%
Random effects model 1.28 [1.16; 1.41] 56.2%
Heterogeneity: I^2 = 61.6%, τ^2 = 0.0527, p < 0.0001
Lung_Function_Impairement_Type = Restrictive
Kulbacka-Ortiz et al., 2022 0.6575 0.2216 1.93 [1.25; 2.98] 1.3%
Kulbacka-Ortiz et al., 2022 0.3507 0.1985 1.42 [0.96; 2.09] 1.5%
Kulbacka-Ortiz et al., 2022 0.0392 0.3229 1.04 [0.55; 1.95] 0.8%
Kulbacka-Ortiz et al., 2022 0.6098 0.2811 1.84 [1.06; 3.19] 1.0%
Kulbacka-Ortiz et al., 2022 0.2151 0.1622 1.24 [0.90; 1.70] 1.8%
Kulbacka-Ortiz et al., 2022 0.5766 0.1859 1.78 [1.24; 2.57] 1.6%
Kulbacka-Ortiz et al., 2022 0.1310 0.2429 1.14 [0.71; 1.84] 1.2%
Kulbacka-Ortiz et al., 2022 0.2700 0.2251 1.31 [0.84; 2.03] 1.3%
Kulbacka-Ortiz et al., 2022 0.4383 0.2348 1.55 [0.98; 2.46] 1.2%
Kulbacka-Ortiz et al., 2022 0.5822 0.2868 1.79 [1.02; 3.14] 0.9%
Kulbacka-Ortiz et al., 2022 0.1906 0.3252 1.21 [0.64; 2.29] 0.8%
Kulbacka-Ortiz et al., 2022 0.6523 0.3377 1.92 [0.99; 3.72] 0.7%
Kulbacka-Ortiz et al., 2022 0.6931 0.2273 2.00 [1.28; 3.12] 1.2%
Kulbacka-Ortiz et al., 2022 0.6627 0.2772 1.94 [1.13; 3.35] 1.0%
Kulbacka-Ortiz et al., 2022 0.5128 0.2275 1.67 [1.07; 2.61] 1.2%
Kulbacka-Ortiz et al., 2022 0.4637 0.3183 1.59 [0.85; 2.96] 0.8%
Kulbacka-Ortiz et al., 2022 0.3507 0.1489 1.42 [1.06; 1.90] 1.9%
Kulbacka-Ortiz et al., 2022 0.6575 0.2308 1.93 [1.23; 3.04] 1.2%
Kulbacka-Ortiz et al., 2022 0.4055 0.3537 1.50 [0.75; 3.00] 0.7%
Kulbacka-Ortiz et al., 2022 1.4207 0.4659 4.14 [1.66; 10.31] 0.4%
Kulbacka-Ortiz et al., 2022 0.3507 0.1958 1.42 [0.97; 2.09] 1.5%
Kulbacka-Ortiz et al., 2022 0.5128 0.2882 1.67 [0.95; 2.94] 0.9%
Kulbacka-Ortiz et al., 2022 0.3148 0.2084 1.37 [0.91; 2.06] 1.4%
Kulbacka-Ortiz et al., 2022 0.8459 0.2657 2.33 [1.38; 3.91] 1.0%
Kulbacka-Ortiz et al., 2022 0.1222 0.1960 1.13 [0.77; 1.66] 1.5%
Kulbacka-Ortiz et al., 2022 -0.1054 0.2329 0.90 [0.57; 1.42] 1.2%
Kulbacka-Ortiz et al., 2022 0.4824 0.2839 1.62 [0.93; 2.83] 0.9%
Kulbacka-Ortiz et al., 2022 0.1570 0.3471 1.17 [0.59; 2.30] 0.7%
Kulbacka-Ortiz et al., 2022 0.4318 0.3412 1.54 [0.79; 3.01] 0.7%
Kulbacka-Ortiz et al., 2022 0.4318 0.1230 1.54 [1.21; 1.96] 2.1%
Kulbacka-Ortiz et al., 2022 0.4447 0.3152 1.56 [0.84; 2.89] 0.8%
Kulbacka-Ortiz et al., 2022 0.2469 0.3377 1.28 [0.66; 2.48] 0.7%
Lindberg et al., 2011 0.3075 0.1675 1.36 [0.98; 1.89] 1.7%
Mannino et al., 2008 0.4055 0.0495 1.50 [1.40; 1.70] 2.8%
Mannino et al.2012 0.7324 0.0745 2.08 [1.80; 2.41] 2.6%
Methvin et al., 2009 0.9933 0.3347 2.70 [1.40; 5.20] 0.7%
Sperandio et al., 2016 2.8629 1.2024 17.51 [1.66; 184.82] 0.1%
Random effects model 1.56 [1.44; 1.69] 43.8%
Heterogeneity: I^2 = 30.3%, τ^2 = 0.0137, p = 0.0439
Random effects model 1.40 [1.31; 1.49] 100.0%
0.5
1
1.5
2
3
4
5
Heterogeneity: I^2 = 59.8%, τ^2 = 0.0362, p < 0.0001
Test for subgroup differences: χ^2_1 = 10.02, df = 1 (p = 0.0015)


Study logOR SE(logOR) Odds Ratio OR 95%-CI Weight
Country = Italy
Di Raimondo et al., 2020 1.2975 0.5491 3.66 [1.29; 11.10] 0.3%
Country = United States
Ferguson et al., 2014 0.4700 0.2958 1.60 [0.90; 2.87] 0.9%
Ferguson et al., 2014 1.0043 0.3850 2.73 [1.28; 5.79] 0.6%
Ferguson et al., 2014 -0.0408 0.4094 0.96 [0.43; 2.14] 0.5%
Kulbaska-Ortiz et al., 2022 0.6931 0.2273 2.00 [1.28; 3.12] 1.2%
Mannino et al., 2008 0.4055 0.0495 1.50 [1.40; 1.70] 2.8%
Mannino et al., 2008 0.0953 0.0734 1.10 [0.90; 1.20] 2.6%
Mannino et al., 2008 0.3365 0.0530 1.40 [1.30; 1.60] 2.8%
Mannino et al., 2008 0.4700 0.0968 1.60 [1.30; 1.90] 2.4%
Methvin et al., 2009 0.9933 0.3347 2.70 [1.40; 5.20] 0.7%
Methvin et al., 2009 0.1823 0.5533 1.20 [0.40; 3.50] 0.3%
Methvin et al., 2009 0.4700 0.3765 1.60 [0.80; 3.50] 0.6%
Methvin et al., 2009 0.4700 0.5083 1.60 [0.60; 4.40] 0.4%
Triest et al., 2019 -0.0408 0.2911 0.96 [0.54; 1.69] 0.9%
Yang et al., 2020 0.1044 0.0436 1.11 [1.02; 1.21] 2.9%
Random effects model 1.41 [1.23; 1.62] 19.8%
Heterogeneity: I^2 = 72.8%, τ^2 = 0.0317, p < 0.0001
Country = Korea
Jo et al., 2015 0.6098 0.1034 1.84 [1.50; 2.25] 2.3%
Kim et al., 2017 0.5365 0.1126 1.71 [1.37; 2.13] 2.2%
Random effects model 1.78 [1.53; 2.07] 4.6%
Heterogeneity: I^2 = 0%, τ^2 = 0, p = 0.6318
Country = Iran
Kiani & Ahmadi, 2021 0.3577 0.1705 1.43 [1.02; 1.99] 1.7%
Country = Turkey
Kulbaska-Ortiz et al., 2022 0.6575 0.2216 1.93 [1.25; 2.98] 1.3%
Triest et al., 2019 -0.2614 0.3453 0.77 [0.39; 1.51] 0.7%
Random effects model 1.27 [0.52; 3.11] 2.0%
Heterogeneity: I^2 = 80.1%, τ^2 = 0.3380, p = 0.0251
Country = Algeria
Kulbaska-Ortiz et al., 2022 0.3507 0.1985 1.42 [0.96; 2.09] 1.5%
Triest et al., 2019 0.9203 0.3212 2.51 [1.34; 4.72] 0.8%
Random effects model 1.79 [1.03; 3.09] 2.2%
Heterogeneity: I^2 = 56.1%, τ^2 = 0.0910, p = 0.1314
Country = Norway
Kulbaska-Ortiz et al., 2022 0.0392 0.3229 1.04 [0.55; 1.95] 0.8%
Triest et al., 2019 -0.0101 0.2818 0.99 [0.57; 1.72] 0.9%
Random effects model 1.01 [0.67; 1.53] 1.7%
Heterogeneity: I^2 = 0%, τ^2 = 0, p = 0.9085
Country = Malawi
Kulbaska-Ortiz et al., 2022 0.6098 0.2811 1.84 [1.06; 3.19] 1.0%
Triest et al., 2019 -1.1087 0.6671 0.33 [0.09; 1.23] 0.2%
Random effects model 0.87 [0.16; 4.61] 1.2%
Heterogeneity: I^2 = 82.3%, τ^2 = 1.2145, p = 0.0176
Country = South Africa
Kulbaska-Ortiz et al., 2022 0.2151 0.1622 1.24 [0.90; 1.70] 1.8%
Triest et al., 2019 -0.2744 0.2125 0.76 [0.50; 1.15] 1.3%
Random effects model 0.99 [0.61; 1.60] 3.1%
Heterogeneity: I^2 = 70.2%, τ^2 = 0.0841, p = 0.0671
Country = Kyrgyztan
Kulbaska-Ortiz et al., 2022 0.5766 0.1859 1.78 [1.24; 2.57] 1.6%
Kulbaska-Ortiz et al., 2022 0.5128 0.2882 1.67 [0.95; 2.94] 0.9%
Triest et al., 2019 0.2927 0.2748 1.34 [0.78; 2.29] 1.0%
Triest et al., 2019 -0.1985 0.3786 0.82 [0.39; 1.72] 0.6%
Random effects model 1.50 [1.15; 1.95] 4.1%
Heterogeneity: I^2 = 18.8%, τ^2 = 0.0052, p = 0.2963
Country = Sri Lanka
Kulbaska-Ortiz et al., 2022 0.1310 0.2429 1.14 [0.71; 1.84] 1.2%
Triest et al., 2019 -0.0101 0.3910 0.99 [0.46; 2.13] 0.6%
Random effects model 1.10 [0.73; 1.64] 1.7%
Heterogeneity: I^2 = 0%, τ^2 = 0, p = 0.7592
Country = Benin
Kulbaska-Ortiz et al., 2022 0.2700 0.2251 1.31 [0.84; 2.03] 1.3%
Triest et al., 2019 -0.1508 0.3196 0.86 [0.46; 1.61] 0.8%
Random effects model 1.13 [0.76; 1.67] 2.1%
Heterogeneity: I^2 = 13.7%, τ^2 = 0.0122, p = 0.2817
Country = Morocco
Kulbaska-Ortiz et al., 2022 0.4383 0.2348 1.55 [0.98; 2.46] 1.2%
Triest et al., 2019 0.0392 0.2477 1.04 [0.64; 1.69] 1.1%
Random effects model 1.28 [0.87; 1.89] 2.3%
Heterogeneity: I^2 = 26.8%, τ^2 = 0.0214, p = 0.2423
Country = China
Kulbaska-Ortiz et al., 2022 0.5822 0.2868 1.79 [1.02; 3.14] 0.9%
Triest et al., 2019 0.2624 0.4595 1.30 [0.53; 3.21] 0.4%
Random effects model 1.64 [1.02; 2.64] 1.4%
Heterogeneity: I^2 = 0%, τ^2 = 0, p = 0.5549
Country = Germany
Kulbaska-Ortiz et al., 2022 0.1906 0.3252 1.21 [0.64; 2.29] 0.8%
Triest et al., 2019 0.4253 0.3277 1.53 [0.80; 2.89] 0.8%
Random effects model 1.36 [0.86; 2.14] 1.5%
Heterogeneity: I^2 = 0%, τ^2 = 0, p = 0.6113
Country = Poland
Kulbaska-Ortiz et al., 2022 0.6523 0.3377 1.92 [0.99; 3.72] 0.7%
Triest et al., 2019 -0.2877 0.3059 0.75 [0.41; 1.36] 0.8%
Random effects model 1.19 [0.47; 2.98] 1.6%
Heterogeneity: I^2 = 76.5%, τ^2 = 0.3380, p = 0.0391
Country = Portugal
Kulbaska-Ortiz et al., 2022 0.6627 0.2772 1.94 [1.13; 3.35] 1.0%
Triest et al., 2019 0.0770 0.0938 1.08 [0.90; 1.30] 2.4%
Random effects model 1.37 [0.78; 2.40] 3.4%
Heterogeneity: I^2 = 75%, τ^2 = 0.1287, p = 0.0454
Country = United Kingdom
Kulbaska-Ortiz et al., 2022 0.5128 0.2275 1.67 [1.07; 2.61] 1.2%
Triest et al., 2019 -0.4308 0.2712 0.65 [0.38; 1.10] 1.0%
Random effects model 1.05 [0.42; 2.66] 2.2%
Heterogeneity: I^2 = 85.9%, τ^2 = 0.3826, p = 0.0077
Country = Netherland
Kulbaska-Ortiz et al., 2022 0.4637 0.3183 1.59 [0.85; 2.96] 0.8%
Triest et al., 2019 0.5933 0.2672 1.81 [1.07; 3.05] 1.0%
Random effects model 1.72 [1.15; 2.56] 1.8%
Heterogeneity: I^2 = 0%, τ^2 = 0, p = 0.7552
Country = Philippines
Kulbaska-Ortiz et al., 2022 0.3507 0.1489 1.42 [1.06; 1.90] 1.9%
Kulbaska-Ortiz et al., 2022 0.6575 0.2308 1.93 [1.23; 3.04] 1.2%
Triest et al., 2019 0.1222 0.2751 1.13 [0.66; 1.94] 1.0%
Triest et al., 2019 -0.4155 0.5168 0.66 [0.24; 1.82] 0.4%
Random effects model 1.41 [1.12; 1.79] 4.5%
Heterogeneity: I^2 = 35.5%, τ^2 = 0.0054, p = 0.1989
Country = India
Kulbaska-Ortiz et al., 2022 0.4055 0.3537 1.50 [0.75; 3.00] 0.7%
Kulbaska-Ortiz et al., 2022 1.4207 0.4659 4.14 [1.66; 10.31] 0.4%
Kulbaska-Ortiz et al., 2022 0.3507 0.1958 1.42 [0.97; 2.09] 1.5%
Triest et al., 2019 -0.1393 0.5065 0.87 [0.32; 2.33] 0.4%
Triest et al., 2019 0.9517 0.5737 2.59 [0.84; 7.96] 0.3%
Triest et al., 2019 0.2311 0.0869 1.26 [1.06; 1.49] 2.5%
Random effects model 1.43 [1.13; 1.81] 5.8%
Heterogeneity: I^2 = 41.9%, τ^2 = 0.0211, p = 0.1251
Country = Malaysia
Kulbaska-Ortiz et al., 2022 0.3148 0.2084 1.37 [0.91; 2.06] 1.4%
Triest et al., 2019 -0.3011 0.5096 0.74 [0.27; 1.99] 0.4%
Random effects model 1.20 [0.73; 1.97] 1.7%
Heterogeneity: I^2 = 20.1%, τ^2 = 0.0381, p = 0.2633
Country = Iceland
Kulbaska-Ortiz et al., 2022 0.8459 0.2667 2.33 [1.38; 3.91] 1.0%
Triest et al., 2019 0.3221 0.2739 1.38 [0.81; 2.37] 1.0%
Random effects model 1.80 [1.08; 3.01] 2.0%
Heterogeneity: I^2 = 46.9%, τ^2 = 0.0644, p = 0.1698
Country = Saudi Arabia
Kulbaska-Ortiz et al., 2022 0.1222 0.1960 1.13 [0.77; 1.66] 1.5%
Triest et al., 2019 0.3293 0.5324 1.39 [0.49; 3.95] 0.3%
Random effects model 1.16 [0.81; 1.66] 1.8%
Heterogeneity: I^2 = 0%, τ^2 = 0, p = 0.7151
Country = Austria
Kulbaska-Ortiz et al., 2022 -0.1054 0.2329 0.90 [0.57; 1.42] 1.2%
Triest et al., 2019 0.1398 0.1847 1.15 [0.80; 1.65] 1.6%
Random effects model 1.05 [0.79; 1.39] 2.8%
Heterogeneity: I^2 = 0%, τ^2 = 0, p = 0.4095
Country = Tunisia
Kulbaska-Ortiz et al., 2022 0.4824 0.2839 1.62 [0.93; 2.83] 0.9%
Triest et al., 2019 0.8459 0.2796 2.33 [1.35; 4.04] 1.0%
Random effects model 1.95 [1.32; 2.88] 1.9%
Heterogeneity: I^2 = 0%, τ^2 = 0, p = 0.3617
Country = Australia
Kulbaska-Ortiz et al., 2022 0.1570 0.3471 1.17 [0.59; 2.30] 0.7%
Triest et al., 2019 -0.6349 0.4236 0.53 [0.23; 1.21] 0.5%
Random effects model 0.82 [0.38; 1.77] 1.2%
Heterogeneity: I^2 = 52.2%, τ^2 = 0.1636, p = 0.1481
Country = Estonia
Kulbaska-Ortiz et al., 2022 0.4318 0.3412 1.54 [0.79; 3.01] 0.7%
Triest et al., 2019 -0.2744 0.3956 0.76 [0.35; 1.65] 0.6%
Random effects model 1.11 [0.56; 2.22] 1.3%
Heterogeneity: I^2 = 45.3%, τ^2 = 0.1129, p = 0.1764
Country = Albania
Kulbaska-Ortiz et al., 2022 0.4318 0.1230 1.54 [1.21; 1.96] 2.1%
Triest et al., 2019 1.0963 0.2106 2.99 [1.98; 4.52] 1.4%
Random effects model 2.10 [1.10; 4.02] 3.5%
Heterogeneity: I^2 = 85.5%, τ^2 = 0.1904, p = 0.0065
Country = Sweden
Kulbaska-Ortiz et al., 2022 0.4447 0.3152 1.56 [0.84; 2.89] 0.8%
Lindberg et al., 2011 0.3075 0.1675 1.36 [0.98; 1.89] 1.7%
Lindberg et al., 2011 0.2311 0.1241 1.26 [0.99; 1.61] 2.1%
Lindberg et al., 2011 0.3436 0.1019 1.41 [1.08; 1.61] 2.4%
Triest et al., 2019 0.1044 0.3410 1.11 [0.57; 2.17] 0.7%
Random effects model 1.35 [1.18; 1.54] 7.7%
Heterogeneity: I^2 = 0%, τ^2 = 0, p = 0.9047
Country = Canada
Kulbaska-Ortiz et al., 2022 0.2469 0.3377 1.28 [0.66; 2.48] 0.7%
Triest et al., 2019 0.2311 0.2873 1.26 [0.72; 2.22] 0.9%
Random effects model 1.27 [0.83; 1.95] 1.7%
Heterogeneity: I^2 = 0%, τ^2 = 0, p = 0.9717
Country = Selected Countries
Mannino et al.2012 0.7324 0.0745 2.08 [1.80; 2.41] 2.6%
Mannino et al.2012 0.3646 0.0708 1.44 [1.25; 1.65] 2.7%
Random effects model 1.73 [1.21; 2.48] 5.3%
Heterogeneity: I^2 = 92.2%, τ^2 = 0.0623, p = 0.0003
Country = Brazil
Sperandio et al., 2016 2.8629 1.2024 17.51 [1.66; 184.82] 0.1%
Random effects model 1.40 [1.31; 1.49] 100.0%
0.1 1 1.5 2 3 4
Heterogeneity: I^2 = 59.8%, τ^2 = 0.0362, p < 0.0001
Test for subgroup differences: χ^2_{10} = 42.36, df = 32 (p = 0.1041)


Study
logOR
SE(logOR)
Odds Ratio
OR
95%-CI
Weight
Study_Design = Cross-Sectional Study
Birhan & Abebe, 2018 3.4500 1.0437 31.50 [4.07; 243.62] 3.6%
Femi-Adeoye et al., 2024 1.1820 0.6061 3.26 [0.99; 10.69] 6.4%
Femi-Adeoye et al., 2024 0.4581 0.3515 1.58 [0.79; 3.15] 8.7%
Femi-Adeoye et al., 2024 0.6345 0.3168 1.89 [1.01; 3.51] 9.0%
Kim et al., 2021 0.8713 0.2563 2.39 [1.45; 3.96] 9.5%
Lee et al., 2020 0.6627 0.2304 1.94 [1.24; 3.06] 9.7%
Taneda et al., 2004 1.4171 0.2899 4.12 [2.34; 7.28] 9.3%
Taneda et al., 2004 1.1669 0.2002 3.21 [2.17; 4.75] 10.0%
Utsugi et al., 2016 0.4855 0.2145 1.62 [1.07; 2.47] 9.9%
Random effects model 2.42 [1.85; 3.15] 76.1%
Heterogeneity: I^2 = 55.7%, τ^2 = 0.0674, p = 0.0206
Study_Design = Case- Control Study
Ferrari et al., 2019 -0.2083 0.1287 0.81 [0.63; 1.04] 10.4%
Patil et al., 2012 2.0849 0.7870 8.04 [1.72; 37.61] 5.0%
Yadav et al., 2015 4.8903 1.2744 133.00 [10.94; 1616.71] 2.7%
Yadav et al., 2015 1.8507 1.1672 6.36 [0.65; 62.70] 3.1%
Yadav et al., 2015 3.1499 1.2669 23.33 [1.95; 279.44] 2.7%
Random effects model 8.19 [1.44; 46.52] 23.9%
Heterogeneity: I^2 = 87.9%, τ^2 = 2.9901, p < 0.0001
Random effects model 3.00 [1.86; 4.82] 100.0%
0.5 1 2 5 10 20 30 50
Heterogeneity: I^2 = 84.7%, τ^2 = 0.5489, p < 0.0001
Test for subgroup differences: χ^2_1 = 1.86, df = 1 (p = 0.1731)


Study
logOR
SE(logOR)
Odds Ratio
OR
95%-CI
Weight
Country = Ethiopia
Birhan & Abebe, 2018 3.4500 1.0437 31.50 [4.07; 243.62] 3.6%
Country = Nigeria
Femi-Adeoye et al., 2024 1.1820 0.6061 3.26 [0.99; 10.69] 6.4%
Femi-Adeoye et al., 2024 0.4581 0.3515 1.58 [0.79; 3.15] 8.7%
Femi-Adeoye et al., 2024 0.6345 0.3168 1.89 [1.01; 3.51] 9.0%
Random effects model 1.89 [1.23; 2.91] 24.2%
Heterogeneity: I^2 = 0%, τ^2 = 0, p = 0.5862
Country = Italy
Ferrari et al., 2019 -0.2083 0.1287 0.81 [0.63; 1.04] 10.4%
Country = Korea
Kim et al., 2021 0.8713 0.2563 2.39 [1.45; 3.96] 9.5%
Lee et al., 2020 0.6627 0.2304 1.94 [1.24; 3.06] 9.7%
Random effects model 2.13 [1.52; 2.98] 19.3%
Heterogeneity: I^2 = 0%, τ^2 = 0, p = 0.5450
Country = India
Patil et al., 2012 2.0849 0.7870 8.04 [1.72; 37.61] 5.0%
Yadav et al., 2015 4.8903 1.2744 133.00 [10.94; 1616.71] 2.7%
Yadav et al., 2015 1.8507 1.1672 6.36 [0.65; 62.70] 3.1%
Yadav et al., 2015 3.1499 1.2669 23.33 [1.95; 279.44] 2.7%
Random effects model 16.30 [4.71; 56.36] 13.5%
Heterogeneity: I^2 = 28.9%, τ^2 = 0.4268, p = 0.2386
Country = United States
Taneda et al., 2004 1.4171 0.2899 4.12 [2.34; 7.28] 9.3%
Taneda et al., 2004 1.1669 0.2002 3.21 [2.17; 4.75] 10.0%
Random effects model 3.48 [2.52; 4.81] 19.2%
Heterogeneity: I^2 = 0%, τ^2 = 0, p = 0.4776
Country = Japan
Utsugi et al., 2016 0.4855 0.2145 1.62 [1.07; 2.47] 9.9%
Random effects model 3.00 [1.86; 4.82] 100.0%
0.5 1 2 5 10 20 30 50
Heterogeneity: I^2 = 84.7%, τ^2 = 0.5489, p < 0.0001
Test for subgroup differences: χ^2_6 = 74.48, df = 6 (p < 0.0001)


Study
logOR
SE(logOR)
Odds Ratio
OR
95%-CI
Weight
Continent = Africa
Birhan & Abebe, 2018 3.4500 1.0437 31.50 [4.07; 243.62] 3.6%
Femi-Adeoye et al., 2024 1.1820 0.6061 3.26 [0.99; 10.69] 6.4%
Femi-Adeoye et al., 2024 0.4581 0.3515 1.58 [0.79; 3.15] 8.7%
Femi-Adeoye et al., 2024 0.6345 0.3168 1.89 [1.01; 3.51] 9.0%
Random effects model 2.89 [1.19; 7.05] 27.7%
Heterogeneity: I^2 = 62.6%, τ^2 = 0.5290, p = 0.0455
Continent = Europe
Ferrari et al., 2019 -0.2083 0.1287 0.81 [0.63; 1.04] 10.4%
Continent = Asia
Kim et al., 2021 0.8713 0.2563 2.39 [1.45; 3.96] 9.5%
Lee et al., 2020 0.6627 0.2304 1.94 [1.24; 3.06] 9.7%
Patil et al., 2012 2.0849 0.7870 8.04 [1.72; 37.61] 5.0%
Utsugi et al., 2016 0.4855 0.2145 1.62 [1.07; 2.47] 9.9%
Yadav et al., 2015 4.8903 1.2744 133.00 [10.94; 1616.71] 2.7%
Yadav et al., 2015 1.8507 1.1672 6.36 [0.65; 62.70] 3.1%
Yadav et al., 2015 3.1499 1.2669 23.33 [1.95; 279.44] 2.7%
Random effects model 4.77 [1.81; 12.58] 42.7%
Heterogeneity: I^2 = 69.6%, τ^2 = 1.1825, p = 0.0031
Continent = North America
Taneda et al., 2004 1.4171 0.2899 4.12 [2.34; 7.28] 9.3%
Taneda et al., 2004 1.1669 0.2002 3.21 [2.17; 4.75] 10.0%
Random effects model 3.48 [2.52; 4.81] 19.2%
Heterogeneity: I^2 = 0%, τ^2 = 0, p = 0.4776
Random effects model 3.00 [1.86; 4.82] 100.0%
0.5
1
2
5
10
15
Heterogeneity: I^2 = 84.7%, τ^2 = 0.5489, p < 0.0001
Test for subgroup differences: χ^2_3 = 56.41, df = 3 (p < 0.0001)


Study
logOR
SE(logOR)
Odds Ratio
OR
95%-CI
Weight
Lung_Function_Impairement_Type = Restrictive
Birhan & Abebe, 2018 3.4500 1.0437 31.50 [4.07; 243.62] 3.6%
Femi-Adeoye et al., 2024 0.4581 0.3515 1.58 [0.79; 3.15] 8.7%
Lee et al., 2020 0.6627 0.2304 1.94 [1.24; 3.06] 9.7%
Taneda et al., 2004 1.4171 0.2899 4.12 [2.34; 7.28] 9.3%
Yadav et al., 2015 4.8903 1.2744 133.00 [10.94; 1616.71] 2.7%
Random effects model 6.32 [1.46; 27.30] 34.0%
Heterogeneity: I^2 = 81.3%, τ^2 = 2.3171, p = 0.0003
Lung_Function_Impairement_Type = Obstructive
Femi-Adeoye et al., 2024 1.1820 0.6061 3.26 [0.99; 10.69] 6.4%
Ferrari et al., 2019 -0.2083 0.1287 0.81 [0.63; 1.04] 10.4%
Kim et al., 2021 0.8713 0.2563 2.39 [1.45; 3.96] 9.5%
Patil et al., 2012 2.0849 0.7870 8.04 [1.72; 37.61] 5.0%
Taneda et al., 2004 1.1669 0.2002 3.21 [2.17; 4.75] 10.0%
Utsugi et al., 2016 0.4855 0.2145 1.62 [1.07; 2.47] 9.9%
Yadav et al., 2015 1.8507 1.1672 6.36 [0.65; 62.70] 3.1%
Random effects model 2.25 [1.29; 3.90] 54.2%
Heterogeneity: I^2 = 87.6%, τ^2 = 0.3721, p < 0.0001
Lung_Function_Impairement_Type = Restrictive and Obstructive
Femi-Adeoye et al., 2024 0.6345 0.3168 1.89 [1.01; 3.51] 9.0%
Lung_Function_Impairement_Type = Mixed
Yadav et al., 2015 3.1499 1.2669 23.33 [1.95; 279.44] 2.7%
Random effects model 3.00 [1.86; 4.82] 100.0%
0.5 1 2 5 10 20 30 50
Heterogeneity: I^2 = 84.7%, τ^2 = 0.5489, p < 0.0001
Test for subgroup differences: χ^2_3 = 5.54, df = 3 (p = 0.1362)


Study
logOR
SE(logOR)
Odds Ratio
OR
95%-CI
Weight
Country = Nigeria
Femi-Adeoye et al., 2024 1.0969 0.4471 3.00 [1.24; 7.17] 8.2%
Country = Korea
Kim et al., 2021 0.7419 0.3189 2.10 [1.12; 3.91] 16.1%
Lee et al., 2020 0.3716 0.2398 1.45 [0.91; 2.33] 28.5%
Random effects model 1.66 [1.14; 2.41] 44.6%
Heterogeneity: I^2 = 0%, τ^2 = 0, p = 0.3533
Country = United States
Taneda et al., 2004 0.8286 0.3247 2.29 [1.21; 4.32] 15.5%
Taneda et al., 2004 0.6931 0.2273 2.00 [1.28; 3.12] 31.7%
Random effects model 2.09 [1.45; 3.01] 47.2%
Heterogeneity: I^2 = 0%, τ^2 = 0, p = 0.7326
Country = Japan
Utsugi et al., 2016 0.0000 . 1.00 0.0%
Random effects model 1.94 [1.51; 2.50] 100.0%
0.8 1 1.5 2 3 4 5
Heterogeneity: I^2 = 0.0%, τ^2 = 0, p = 0.5992
Test for subgroup differences: χ^2_2 = 1.78, df = 2 (p = 0.4108)


Study
logOR
SE(logOR)
Odds Ratio
OR
95%-CI
Weight
Continent = Africa
Femi-Adeoye et al., 2024 1.0969 0.4471 3.00 [1.24; 7.17] 8.2%
Continent = Asia
Kim et al., 2021 0.7419 0.3189 2.10 [1.12; 3.91] 16.1%
Lee et al., 2020 0.3716 0.2398 1.45 [0.91; 2.33] 28.5%
Utsugi et al., 2016 0.0000 . 1.00 0.0%
Random effects model 1.66 [1.14; 2.41] 44.6%
Heterogeneity: I^2 = 0%, τ^2 = 0, p = 0.3533
Continent = North America
Taneda et al., 2004 0.8286 0.3247 2.29 [1.21; 4.32] 15.5%
Taneda et al., 2004 0.6931 0.2273 2.00 [1.28; 3.12] 31.7%
Random effects model 2.09 [1.45; 3.01] 47.2%
Heterogeneity: I^2 = 0%, τ^2 = 0, p = 0.7326
Random effects model 1.94 [1.51; 2.50] 100.0%
0.5
1
1.5
2
3
4
5
Heterogeneity: I^2 = 0.0%, τ^2 = 0, p = 0.5992
Test for subgroup differences: χ^2_2 = 1.78, df = 2 (p = 0.4108)


Study
logOR
SE(logOR)
Odds Ratio
OR
95%-CI
Weight
Lung_Function_Impairement_Type = Restrictive and Obstructive
Femi-Adeoye et al., 2024 1.0969 0.4471 3.00 [1.24; 7.17] 8.2%
Lung_Function_Impairement_Type = Obstructive
Kim et al., 2021 0.7419 0.3189 2.10 [1.12; 3.91] 16.1%
Taneda et al., 2004 0.6931 0.2273 2.00 [1.28; 3.12] 31.7%
Utsugi et al., 2016 0.0000 . 1.00 0.0%
Random effects model 2.03 [1.41; 2.92] 47.8%
Heterogeneity: I^2 = 0%, τ^2 = 0, p = 0.9009
Lung_Function_Impairement_Type = Restrictive
Lee et al., 2020 0.3716 0.2398 1.45 [0.91; 2.33] 28.5%
Taneda et al., 2004 0.8286 0.3247 2.29 [1.21; 4.32] 15.5%
Random effects model 1.73 [1.12; 2.67] 44.0%
Heterogeneity: I^2 = 22%, τ^2 = 0.0230, p = 0.2576
Random effects model 1.94 [1.51; 2.50] 100.0%
0.5
1
1.5
2
3
4
5
Heterogeneity: I^2 = 0.0%, τ^2 = 0, p = 0.5992
Test for subgroup differences: χ^2_2 = 1.25, df = 2 (p = 0.5358)


Chronic Lung Diseases
Hypoxia
Systemic inflammation
Inhibition of pulmonary stretch receptors
Vascular stiffness ↑
Arterial compliance ↓
Endothelial dysfunction ↑
Autonomic nerve imbalances
Muscle sympathetic nerve activity ↑
Sympathetic nerve activity ↑
Parasympathetic nervous system ↓
Baroreceptor sensitivity ↓
Hypertension
CVDs